<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Chim Acta</journal-id><journal-id journal-id-type="iso-abbrev">Clin. Chim. Acta</journal-id><journal-title-group><journal-title>Clinica Chimica Acta; International Journal of Clinical Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0009-8981</issn><issn pub-type="epub">1873-3492</issn><publisher><publisher-name>Elsevier B.V.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7256510</article-id><article-id pub-id-type="publisher-id">S0009-8981(20)30250-3</article-id><article-id pub-id-type="doi">10.1016/j.cca.2020.05.044</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>COVID-19: Transmission, prevention, and potential therapeutic opportunities</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name><surname>Lotfi</surname><given-names>Melika</given-names></name><xref rid="af005" ref-type="aff">a</xref><xref rid="af010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au010"><name><surname>Hamblin</surname><given-names>Michael R.</given-names></name><xref rid="af015" ref-type="aff">c</xref><xref rid="af020" ref-type="aff">d</xref><xref rid="af025" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au015"><name><surname>Rezaei</surname><given-names>Nima</given-names></name><email>rezaei_nima@tums.ac.ir</email><xref rid="af030" ref-type="aff">f</xref><xref rid="af035" ref-type="aff">g</xref><xref rid="af040" ref-type="aff">h</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib><aff id="af005"><label>a</label>School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran</aff><aff id="af010"><label>b</label>Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Zanjan, Iran</aff><aff id="af015"><label>c</label>Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA</aff><aff id="af020"><label>d</label>Laser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein 2028, South Africa</aff><aff id="af025"><label>e</label>Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Boston, MA, USA</aff><aff id="af030"><label>f</label>Research Center for Immunodeficiencies, Children&#x02019;s Medical Center, Tehran University of Medical Sciences, Tehran, Iran</aff><aff id="af035"><label>g</label>Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran</aff><aff id="af040"><label>h</label>Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Stockholm, Sweden</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x0204e;</label>Corresponding author at: Research Center for Immunodeficiencies, Children's Medical Center Hospital, Dr. Qarib St, Keshavarz Blvd, Tehran 14194, Iran. <email>rezaei_nima@tums.ac.ir</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>29</day><month>5</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>9</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>29</day><month>5</month><year>2020</year></pub-date><volume>508</volume><fpage>254</fpage><lpage>266</lpage><history><date date-type="received"><day>29</day><month>4</month><year>2020</year></date><date date-type="rev-recd"><day>22</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>26</day><month>5</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Elsevier B.V. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Elsevier B.V.</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract abstract-type="author-highlights" id="ab005"><title>Highlights</title><p><list list-type="simple" id="l0005"><list-item id="o0005"><label>&#x02022;</label><p id="p0005">Novel coronavirus disease (COVID-19) is a global issue nowadays.</p></list-item><list-item id="o0010"><label>&#x02022;</label><p id="p0010">COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).</p></list-item><list-item id="o0015"><label>&#x02022;</label><p id="p0015">The current knowledge about the treatment protocol is still limited.</p></list-item><list-item id="o0020"><label>&#x02022;</label><p id="p0020">Preventing the virus can be the best way of controlling the pandemic.</p></list-item></list></p></abstract><abstract id="ab010"><p>The novel coronavirus disease (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global challenge. Despite intense research efforts worldwide, an effective vaccine and viable treatment options have eluded investigators. Therefore, infection prevention, early viral detection and identification of successful treatment protocols provide the best approach in controlling disease spread. In this review, current therapeutic options, preventive methods and transmission routes of COVID-19 are discussed.</p></abstract><kwd-group id="kg005"><title>Keywords</title><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>Treatment</kwd><kwd>Transmission</kwd><kwd>Prevention</kwd></kwd-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0025">Although the emergence of new coronavirus diseases, probably originating from bats in China, had been predicted by early March 2019 <xref rid="b0005" ref-type="bibr">[1]</xref>, no international preventive action was taken. Finally, after several cases of pneumonia with an unfamiliar etiology were observed at the end of 2019, the National Health Commission of China released more details about the epidemic in early 2020 <xref rid="b0010" ref-type="bibr">[2]</xref>. The causative virus was initially called &#x0201c;novel coronavirus 2019&#x0201d; (2019-nCoV) by the World Health Organization (WHO), but it was then renamed as &#x0201c;severe acute respiratory syndrome coronavirus 2&#x0201d; (SARS-CoV-2) by the international committee of the Coronavirus Study Group (CSG), and the disease called &#x0201c;coronavirus disease 2019&#x0201d; (COVID-19) by WHO <xref rid="b0015" ref-type="bibr">[3]</xref>. It is thought that the Hunan seafood market in Wuhan city in China was the origin of the outbreak. Although it had been proposed that the COVID-19 patients in China might have utilized infected animals as a foodstuff, or might have visited the seafood market, further investigation revealed that some patients had not visited the seafood market. Therefore, the human-to-human transmission of this virus through coughing, sneezing, and the spread of respiratory droplets or aerosols was accepted. In addition, almost all countries in continents throughout the world reported disease spread caused by aerosol penetration into the upper the respiratory tract and lungs via inhalation <xref rid="b0020" ref-type="bibr">[4]</xref>, <xref rid="b0025" ref-type="bibr">[5]</xref>. There followed a rapid growth in the number of cases all around the world. A mathematical model examined whether the control of SARS-CoV-2 infection could be achieved by isolating affected patients, and tracking their contacts with other individuals. This model concluded that isolating people and reviewing their contacts would be insufficient to control the COVID-19 pandemic within three months, because there would be too much delay between the onset of symptoms and isolation <xref rid="b0030" ref-type="bibr">[6]</xref>. Thus, observing preventive measures, especially isolation and lockdown, would be essential.</p><p id="p0030">SARS-CoV-2 is highly contagious, and there has not yet been any vaccine or effective treatment that has received approval. So, the best solution for controlling the pandemic will be the simultaneous application of preventive methods, sensitive diagnostic approaches, and using current available drugs, while still developing novel treatments <xref rid="b0035" ref-type="bibr">[7]</xref>, <xref rid="b0040" ref-type="bibr">[8]</xref>, <xref rid="b0045" ref-type="bibr">[9]</xref>. This study presents the latest information about COVID-19 transmission, prevention, and potential therapeutic options.</p></sec><sec id="s0010"><label>2</label><title>SARS-CoV-2 characteristics</title><p id="p0035">SARS-CoV-2 is an enveloped, positive-sense, and single-stranded 29.9&#x000a0;kb RNA beta-coronavirus <xref rid="b0050" ref-type="bibr">[10]</xref>, <xref rid="b0055" ref-type="bibr">[11]</xref>. Investigation of the SARS-CoV-2 genome proved that it has 88% similarity with the bat-SL-CoVZC45 and bat-SL-CoVZXC21 sequences, and was 96.2% identical to another bat CoV RaTG13 <xref rid="b0060" ref-type="bibr">[12]</xref>. However, some recent investigations have suggested that pangolins that were smuggled from Malaysia to China, along with other possible intermediate hosts like turtles or snakes could be the direct origin of the virus instead of a bat <xref rid="b0065" ref-type="bibr">[13]</xref>.</p><p id="p0040">Moreover, the protein-coding genes of SARS-CoV-2 have 79.5% and 51% sequence similarity to SARS-CoV and MERS-CoV, respectively. The SARS-CoV-2 virus employs the Angiotensin-Converting Enzyme 2 (ACE2) receptor for cellular entry, similar to SARS-CoV <xref rid="b0015" ref-type="bibr">[3]</xref>, <xref rid="b0070" ref-type="bibr">[14]</xref>. Therefore, previous treatments that were used to control the SARS-CoV and MERS-CoV epidemics, might also be effective in SARS-CoV-2.</p></sec><sec id="s0015"><label>3</label><title>Clinical consequences</title><p id="p0045">The first symptoms are commonly recognized as fever, dry cough, tachypnea, and shortness of breath <xref rid="b0075" ref-type="bibr">[15]</xref>. Although diarrhea was present in about 20&#x02013;25% of patients with MERS-CoV or SARS-CoV infection, intestinal symptoms are rarely seen in patients with COVID-19. In another study, confusion, chest pain, vomiting, and nausea were also reported as COVID-19 symptoms <xref rid="b0080" ref-type="bibr">[16]</xref>. Other symptoms include, sore throat, sneezing, nasal congestion, sputum production, anosmia and dyspepsia, rash on the skin, or discoloration of fingers or toes, and viral conjunctivitis. Some laboratory studies have shown the occurrence of cytokine storm, sepsis, and RNAaemia in COVID-19 <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0090" ref-type="bibr">[18]</xref>.</p><p id="p0050">Clinical chemistry studies have shown increases in lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine transaminase (ALT), C-reactive protein (CRP), creatine kinase (CK), erythrocyte sedimentation rate (ESR), white blood cell (WBC) count, D-dimer level, procalcitonin, urea, and creatinine. Decreases in hemoglobin, lymphocyte count, eosinophil count, and serum albumin have been detected in COVID-19 patients <xref rid="b0085" ref-type="bibr">[17]</xref>.</p><p id="p0055">The most common radiological findings in patients with COVID-19 were a ground-glass opacity in the lungs <xref rid="b0095" ref-type="bibr">[19]</xref>. Moreover, SARS-CoV-2 can affect the cardiovascular system <xref rid="b0080" ref-type="bibr">[16]</xref>, gastrointestinal tract <xref rid="b0100" ref-type="bibr">[20]</xref>, and can cause acute kidney failure <xref rid="b0010" ref-type="bibr">[2]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>. Moreover, evaluation of liver manifestations in 148 patients with COVID-19 indicated that more than one-third of the COVID-19 patients admitted to the hospital had abnormal liver function, and these patients were hospitalized for a more extended period <xref rid="b0105" ref-type="bibr">[21]</xref>. It must be mentioned that it is likely that a substantial number of asymptomatic patients can be carriers of the virus. The variable clinical manifestations and outcomes underline the importance of adhering to hygienic and preventive principles, in addition to finding and developing new sensitive diagnostic approaches and therapeutic options.</p></sec><sec id="s0020"><label>4</label><title>Infection in children</title><p id="p0060">Unlike adults, children with COVID-19 have milder symptoms and better clinical outcomes <xref rid="b0110" ref-type="bibr">[22]</xref>; among the COVID-19 patients under 18&#x000a0;years of age, children under one year old seem to be at the highest risk of the severe form of the disease <xref rid="b0115" ref-type="bibr">[23]</xref>. Although early studies showed that children with COVID-19 were less likely to develop severe symptoms than other age groups, one new study has shown that children are as likely to develop COVID-19 as adults <xref rid="b0120" ref-type="bibr">[24]</xref>. So, prevention and finding appropriate treatment for children is as important as for adults.</p><p id="p0065">In one study, 1391 children with a median age of 6.7&#x000a0;years were surveyed, and 171 were diagnosed with COVID-19. Intensive Care Unit (ICU) and mechanical ventilation were needed for only three children, who had underlying conditions. By March 8th, 2020, one child with intussusception had died, 21 children remained in a stable condition in the ward, and 149 cases were discharged <xref rid="b0125" ref-type="bibr">[25]</xref>.</p><p id="p0070">It should be mentioned that recently scientists and clinicians have reported that young infants who were diagnosed with COVID-19, also had classic Kawasaki disease (KD) or a KD-like disease, which indicates that more investigation into the clinical manifestations of pediatric COVID-19 and its potential association with KD is needed <xref rid="b0130" ref-type="bibr">[26]</xref>.</p></sec><sec id="s0025"><label>5</label><title>Transmission of COVID-19</title><p id="p0075">SARS-CoV-2 can spread through both direct means (droplet and human-to-human transmission) and by indirect contact (contaminated objects and airborne contagion). Meanwhile personal protective equipment (PPE) could also be the source of airborne infections <xref rid="b0135" ref-type="bibr">[27]</xref>. As mentioned before, person-to-person spread of SARS-CoV-2 is supposed to occur mainly via respiratory droplets, when a patient coughs, sneezes, or even talks or sings. Droplets typically cannot traverse more than six feet (almost two meters) and remain in the air for a limited time. However, SARS-CoV-2 remains intact and contagious in droplets (less than five microns in diameter) and can be suspended in the air for up to three hours <xref rid="b0140" ref-type="bibr">[28]</xref>. Therefore, airborne isolation, room ventilation, and appropriate application of disinfectant (especially in toilets) might restrict aerosol spread of the virus <xref rid="b0145" ref-type="bibr">[29]</xref>.</p><p id="p0080">COVID-19 can occur if a person touches a surface contaminated with SARS-CoV-2, and then the hands come into direct contact with mucous membranes such as the eyes, nose, or mouth <xref rid="b0150" ref-type="bibr">[30]</xref>. Thus, sufficient washing of hands with soap and water or hand sanitizers is recommended.</p><p id="p0085">The reported contagion rates from a patient with symptomatic infection vary by location and efficiency of infection control measures. Based on a joint WHO-China report, the rate of secondary COVID-19 infection ranged from one to five percent among tens of thousands of confirmed patients in China <xref rid="b0150" ref-type="bibr">[30]</xref>.</p><p id="p0090">The spread of SARS-CoV-2 from asymptomatic individuals (or individuals within the incubation period), without any radiological findings, has also been reported <xref rid="b0155" ref-type="bibr">[31]</xref>, <xref rid="b0160" ref-type="bibr">[32]</xref>, <xref rid="b0165" ref-type="bibr">[33]</xref>. Therefore, there is a need for improvements in rapid and sensitive diagnostic methods for detecting infected individuals.</p><p id="p0095">In a study on four hospital staff who became infected, although each patient had at least two negative tests, the RT-PCR was still positive from 5 to 13&#x000a0;days after being discharged <xref rid="b0170" ref-type="bibr">[34]</xref>. Also, viral shedding in the stool likely occurs up for to five weeks (the longest time of shedding was 37&#x000a0;days <xref rid="b0175" ref-type="bibr">[35]</xref> and in deceased patients until the moment of death) with a mean of 11.2&#x000a0;days after the respiratory tract test was negative <xref rid="b0180" ref-type="bibr">[36]</xref>. So, because SARS-CoV-2 can be transmitted from recovered patients, it is wise to change the current discharge criteria. The current discharge criteria are as follows:</p><p id="p0100">(1) Two consecutive RT-PCR negative results in at least a 24&#x000a0;h interval; (2) Complete resolution of the patient's acute exudative pulmonary lesions on chest Computed Tomography (CT) examination; (3) Normalization of temperature for over 72&#x000a0;h; and (4) Resolution of the patient's respiratory symptoms <xref rid="b0170" ref-type="bibr">[34]</xref>, <xref rid="b0185" ref-type="bibr">[37]</xref>.</p><p id="p0105">Although SARS-CoV-2 RNA has been discovered in blood and stool samples <xref rid="b0190" ref-type="bibr">[38]</xref> and living SARS-CoV-2 has been cultured from stool in some COVID-19 patients <xref rid="b0195" ref-type="bibr">[39]</xref>, a joint WHO-China report indicated that fecal-oral transmission route did not appear to be an important factor in the spread of infection <xref rid="b0150" ref-type="bibr">[30]</xref>.</p><p id="p0110">It should be mentioned that a study of semen and testicular specimens of COVID-19 patients suggested that SARS-CoV-2 could not be transmitted through sexual contact <xref rid="b0200" ref-type="bibr">[40]</xref>.</p><p id="p0115">As pregnant women are at a high risk of contracting COVID-19, investigating the possible vertical transmission of COVID-19 is important. An infant delivered from an affected mother was reported to test negative for seven duplicate samples of neonatal blood, stool, and oropharynx <xref rid="b0205" ref-type="bibr">[41]</xref>; however, recent studies showed immunoglobulin M (IgM) antibodies to SARS-CoV-2 were present in newborn infant blood; so, possible transmission of SARS-CoV-2 from mother to fetus could not be ruled out <xref rid="b0210" ref-type="bibr">[42]</xref>, <xref rid="b0215" ref-type="bibr">[43]</xref>.</p><p id="p0120">Although it is unknown whether the SARS-CoV-2 was transmitted from infected animals (civet cat, snake, or other species) to humans at the Huanan seafood market or not, there is a clear possibility for animal-to-human transmission <xref rid="b0220" ref-type="bibr">[44]</xref>. Ferrets, cats, dogs, and other domesticated animals are susceptible to SARS-CoV-2 <xref rid="b0225" ref-type="bibr">[45]</xref>. It has been demonstrated that cats can be infected with SARS-CoV-2 and transmit it to other cats. Nevertheless, it is not yet clear if cats can transmit the virus to their owners; so at present this not a problem for cat owners. Moreover, ducks, pigs, chickens, and dogs are not likely to be infected. However, it should be mentioned that a German shepherd pet dog died (the cause of death could not be determined as the owner declined to conduct an autopsy) two days after the owner was in COVID-19 quarantine <xref rid="b0230" ref-type="bibr">[46]</xref>. So, possible animal-to-human transmission of the virus must be taken into account.</p><p id="p0125">Based on the above-mentioned evidence, transmission of the virus could be more complicated than that seen in previous pandemics. The virus is highly contagious, and there is no successful treatment or a vaccine. Also, a relatively long incubation period, presence of asymptomatic patients, and continued viral shedding after recovery all underline the importance of home quarantine through lockdown of the entire society like the Chinese government carried out <xref rid="b0235" ref-type="bibr">[47]</xref>.</p></sec><sec id="s0030"><label>6</label><title>Temperature and humidity and SARS-CoV-2 infection</title><p id="p0130">One study investigated the relationship between the mean daily average temperature and the average rate of increase of new patients with COVID-19. Five countries (Iran, Italy, Germany, Spain, and United States) were studied. To minimize the impact of confounding factors like the imposition of government measures or cultural differences between these countries, different areas in each country were compared separately. The results of this study found that in all studied areas, a significant difference in the average daily air temperature between the two regions was associated with a substantial difference in the daily average cumulative rate of new patients in those two regions <xref rid="b0240" ref-type="bibr">[48]</xref>.</p><p id="p0135">In addition, the average temperature and humidity of infected cities were found to be 5&#x000a0;&#x000b0;C to 11&#x000a0;&#x000b0;C and 47 to 79%, respectively, and the optimum temperature and humidity for the survival of SARS-CoV-2 <italic>in vitro</italic> were 4&#x000a0;&#x000b0;C and 20 to 80%, respectively. Also, the average temperature in the contaminated cities was never below zero degrees Celsius. Additionally, the virus spread in the latitude corridor was 30 to 50&#x000b0;north (South Korea, Japan, Iran, and North Italy). Furthermore, at this time, the SARS-CoV-2 had not been able to spread quickly in southern China <xref rid="b0245" ref-type="bibr">[49]</xref>.</p><p id="p0140">Although the above-mentioned reports suggest a relationship between temperature and the distribution of the virus, comparing the global climate and COVID-19 distribution maps <xref rid="b0250" ref-type="bibr">[50]</xref>, <xref rid="b0255" ref-type="bibr">[51]</xref>, it could be concluded that there was no significant relationship between temperature, humidity, and the virus distribution.</p></sec><sec id="s0035"><label>7</label><title>Preventive approaches</title><p id="p0145">The WHO has stated that education, isolation, prevention, controlling the transmission, and treatment of infected persons are the critical steps in controlling contagious diseases like COVID-19 <xref rid="b0260" ref-type="bibr">[52]</xref>. It is possible to minimize the spread of infection by making the following recommendations.</p><p id="p0150">Staying at home (home quarantine) and avoiding any direct contact with any healthy (possible asymptomatic patients) or infected person, which has been called shielding; avoiding nonessential travel; observing social distancing rules like avoiding crowded public places and maintaining at least two meters of distance between each person, especially if they are coughing or sneezing; avoiding shaking hands when greeting others; frequently washing hands for at least 20&#x000a0;s with soap and water or hand sanitizer with at least 60% alcohol, especially after touching common surface areas, using the bathroom, or shaking hands, avoiding touching eyes, nose, and mouth with unwashed hands; and disinfecting surfaces using household sprays or wipes.</p><p id="p0155">It should be mentioned that due to the long incubation period and presence of asymptomatic patients, using a medical mask (especially N95) or a respirator (especially FFP3) could be recommended. Also, sterilizing the used respirator, only reusing it for a limited time, and proper disposal of the used masks, have been recommended. Although respirators (the protective classes, including FFP1, FFP2, and FFP3 <xref rid="b0265" ref-type="bibr">[53]</xref>) are produced as single-use items, they could be used again for a limited time unless there is a risk for contamination through the deposition of infectious particles on the surface <xref rid="b0270" ref-type="bibr">[54]</xref>. When the respirator becomes soiled or wet with bodily fluids or it can no longer be appropriately fitted, or if breathing via the respirator becomes difficult, it should be discarded. Also, masks should be discarded after being used during an aerosol-generating procedure (AGP). Until now, manufacturers have had no reason to disinfect masks or to produce masks for repeated use. However, there is a vital need to be able to disinfect masks and reuse them. SARS-CoV-2 remains viable in the environment, including on the surface of different materials like cardboard, iron, or tissue for some time. This suggests that there is a risk for rapid contamination of the outer surface of respirators and surgical masks. Contamination of the respirator surface could be prevented through placing a medical mask over it, or wearing a face shield that can be cleaned. Because of the severe contamination of respirators and surgical masks in the COVID-19 pandemic, several methods could be considered for the sterilization of used masks, including steam, hydrogen peroxide, or radiation.</p><p id="p0160">Besides, the use of medical shields or wearing protective suits is recommended, especially for health care workers. It should be mentioned that wearing gloves in public is not an adequate protection against COVID-19, because gloves can easily be contaminated. So, frequent washing of hands is the best way to protect against SARS-CoV-2 infection <xref rid="b0275" ref-type="bibr">[55]</xref>.</p><p id="p0165">A study in six departments of a hospital in Wuhan, China demonstrated that the use of N95 masks, disinfectants, and handwashing by doctors and nurses were effective in preventing against COVID-19 infection <xref rid="b0280" ref-type="bibr">[56]</xref>.</p><p id="p0170">In terms of vaccines, there are a large number of vaccination strategies against SARS-CoV, MERS-CoV being tested in animals, including a live-attenuated virus, viral vectors, inactivated virus, subunit vaccines, recombinant DNA, and proteins vaccines (1&#x000a0;1&#x000a0;6). Although, until now, there has not been any approved vaccine against SARS-CoV-2, several clinical trials have been launched for testing the effects of various vaccines against SARS-CoV-2.</p></sec><sec id="s0040"><label>8</label><title>COVID-19 therapeutic options</title><p id="p0175">Huang <italic>et al.</italic>
<xref rid="b0285" ref-type="bibr">[57]</xref> reported that acute respiratory distress syndrome (ARDS) was the most common complication in COVID-19 patients <xref rid="b0290" ref-type="bibr">[58]</xref>, followed by anemia, acute cardiac injury, and secondary infections. Hence, empirical antibiotics, antiviral drugs, and systemic corticosteroids are used as treatments <xref rid="b0295" ref-type="bibr">[59]</xref>. Moreover, Holshue <italic>et al.</italic>
<xref rid="b0300" ref-type="bibr">[60]</xref> suggested the use of invasive mechanical ventilation for patients with intractable hypoxemia. So, the treatments of patients with COVID-19 infection are mainly symptomatic in nature.</p><p id="p0180">It should be mentioned that the panel of National Institutes of Health (NIH) does not recommend the application of any agent for pre- or post-exposure prophylaxis against SARS-CoV-2 outside the setting of a clinical trial <xref rid="b0305" ref-type="bibr">[61]</xref>. Except for the clinical trials, some medications are not recommended for use in the clinic, like the combination of Hydroxychloroquine and Azithromycin because of the potential for toxicity. Other conceivable treatments are not recommended such as Lopinavir/Ritonavir or other&#x000a0;protease inhibitors (used for human immunodeficiency virus (HIV)) because of unfavorable pharmacodynamics and negative clinical trial data, Interferons because of lack of efficacy in the treatment of SARS and MERS, Janus kinase inhibitors (e.g., Baricitinib <xref rid="b0310" ref-type="bibr">[62]</xref>) because of their broad immunosuppressive effects, and systemic corticosteroids during the treatment of mechanically ventilated patients with COVID-19 without ARDS.</p><p id="p0185">Scientists are trying hard to develop new potential therapeutic strategies, consisting of monoclonal antibodies, vaccines, peptides, Interferon-based therapies, protease inhibitors, and small-molecule drugs to defeat the COVID-19 pandemic. However, it might take several months to test their efficacy <italic>in vitro</italic> and <italic>in vivo</italic>, and the results of clinical trials may take even longer. In order to shorten this time, WHO is organizing a large clinical trial (Solidarity clinical trial), encompassing over 100 countries from all around the world.</p><sec id="s0045"><label>8.1</label><title>Virally targeted agents</title><p id="p0190">Antiviral drugs and systemic corticosteroids, including neuraminidase inhibitors (Oseltamivir, Peramivir, and Zanamivir), Ganciclovir, Acyclovir, and Ribavirin, as well as Methylprednisolone which reduced the risk of death in ARDS patients <xref rid="b0315" ref-type="bibr">[63]</xref>, <xref rid="b0320" ref-type="bibr">[64]</xref>, <xref rid="b0325" ref-type="bibr">[65]</xref>, are used in the clinic for viral infections. However, they have not been shown to have any effect on COVID-19, thus they are not recommended <xref rid="b0330" ref-type="bibr">[66]</xref>.</p><sec id="s0050"><label>8.1.1</label><title>Nucleoside analogs</title><p id="p0195">Nucleoside analogs are derivatives of adenine or guanine that block the RNA-dependent RNA polymerase enzyme and affect the structure of viral RNA in a large spectrum of RNA viruses, including human coronaviruses <xref rid="b0335" ref-type="bibr">[67]</xref>.</p><sec id="s0055"><label>8.1.1.1</label><title>Favipiravir (T-705)</title><p id="p0200">Favipiravir is a guanine analog that is approved for influenza treatment. It can inhibit the RNA-dependent RNA polymerase of RNA viruses such as Influenza, Yellow fever, Chikungunya, Ebola <xref rid="b0340" ref-type="bibr">[68]</xref>, Norovirus, and Enterovirus <xref rid="b0335" ref-type="bibr">[67]</xref>. Besides, in one recent study, scientists have reported its effectiveness against 2019-nCoV <xref rid="b0345" ref-type="bibr">[69]</xref>. Patients with COVID-19 are being enrolled in randomized clinical trials to test the efficacy of Favipiravir plus Interferon-&#x003b1; (ChiCTR2000029600), and Favipiravir plus Baloxavir marboxil (an approved Influenza inhibitor targeting the cap-dependent endonuclease) (ChiCTR2000029544).</p></sec><sec id="s0060"><label>8.1.1.2</label><title>Favilavir</title><p id="p0205">Favilavir is an approved treatment for Influenza, which inhibits the RNA-dependent RNA polymerase. It has been approved as an experimental coronavirus drug against SARS-CoV-2 <xref rid="b0350" ref-type="bibr">[70]</xref>.</p></sec><sec id="s0065"><label>8.1.1.3</label><title>Ribavirin</title><p id="p0210">Ribavirin is a guanine derivative approved for treating respiratory syncytial virus (RSV) and hepatitis C virus (HCV) infections, which also showed positive results in patients with SARS and MERS, but its side effects such as anemia may be severe at high doses <xref rid="b0355" ref-type="bibr">[71]</xref>. Besides, its potency against SARS-CoV-2 is unknown <xref rid="b0360" ref-type="bibr">[72]</xref>, <xref rid="b0365" ref-type="bibr">[73]</xref>. One in-silico study revealed the potential ability of Sofosbuvir, Ribavirin, and Remdesevir to inhibit SARS-CoV-2 polymerase <xref rid="b0370" ref-type="bibr">[74]</xref>. However, another study, mentioned above, ruled it out as an effective therapy for COVID-19. So, it is not yet clear whether it is effective against COVID-19 or not, and more investigation is needed.</p></sec><sec id="s0070"><label>8.1.1.4</label><title>Remdesivir (GS-5734)</title><p id="p0215">Remdesivir is a phosphoramidite pro-drug of an adenine derivative with a chemical structure similar to Tenofovir alafenamide, an approved inhibitor of HIV reverse transcriptase. Remdesivir had broad-spectrum activity against a diverse range of coronaviruses, including human CoVs, zoonotic bat CoVs, and pre-pandemic zoonotic CoVs, in addition to Ebola in cell culture and animal models <xref rid="b0375" ref-type="bibr">[75]</xref>. The results of the latest studies suggested that Remdesivir can inhibit 2019-nCoV <xref rid="b0345" ref-type="bibr">[69]</xref>, <xref rid="b0380" ref-type="bibr">[76]</xref>. Moreover, a phase III clinical trial of Remdesivir against COVID-19 was launched in Wuhan on February 4th, 2020. Remdesivir is not expected to be widely available as an experimental drug for treating a vast number of patients <xref rid="b0385" ref-type="bibr">[77]</xref>. However, the Food and Drug Administration (FDA) has approved Remdesivir as an effective COVID-19 treatment <xref rid="b0390" ref-type="bibr">[78]</xref>.</p></sec><sec id="s0075"><label>8.1.1.5</label><title>Galidesivir (BCX4430)</title><p id="p0220">Galidesivir is an adenosine analog that was initially developed to treat HCV, and its efficacy against Yellow fever revealed its antiviral activity in preclinical studies against many RNA viruses, including SARS-CoV and MERS-CoV <xref rid="b0355" ref-type="bibr">[71]</xref>. At present, it is in primary clinical trials to assess its safety in healthy individuals. So, it might be useful against SARS-CoV-2.</p></sec><sec id="s0080"><label>8.1.1.6</label><title>Protease inhibitors</title><sec id="s0085"><label>8.1.1.6.1</label><title>Chymotrypsin-like (3C-like protease, 3CLpro) and papain-like protease (PLP) inhibitors</title><p id="p0225">3C-like protease or 3CLpro and PLP are non-structural proteins, which play a critical role in the replication of coronaviruses, and can also inhibit the host innate immune responses <xref rid="b0395" ref-type="bibr">[79]</xref>. So, 3CLpro inhibitors and PLP inhibitors might be effective against SARS-CoV-2.</p></sec><sec id="s0090"><label>8.1.1.6.2</label><title>Lopinavir</title><p id="p0230">Lopinavir was primarily supposed to inhibit the 3-chymotrypsin-like protease of SARS and MERS. Although it improved the clinical outcomes in SARS patients in a non-randomized open-label trial <xref rid="b0355" ref-type="bibr">[71]</xref>, it is questionable whether HIV protease inhibitors could effectively inhibit the 3-chymotrypsin-like and papain-like proteases of SARS-CoV-2 or not. This is because the molecular design of HIV protease inhibitors was explicitly optimized to fit the C2 symmetry in the catalytic site of the HIV protease dimer, however, this C2-symmetric pocket is absent in coronavirus proteases <xref rid="b0400" ref-type="bibr">[80]</xref>. In contrast to previous studies that showed after administration of Lopinavir/Ritonavir, &#x003b2;-coronavirus the viral loads were significantly reduced, and coronavirus titers were low or absent <xref rid="b0405" ref-type="bibr">[81]</xref>, it has been shown that the combination of Lopinavir and Ritonavir is not effective in treating patients with severe COVID-19 <xref rid="b0410" ref-type="bibr">[82]</xref>.</p></sec><sec id="s0095"><label>8.1.1.6.3</label><title>Disulfiram</title><p id="p0235">Disulfiram is a drug used for treating chronic alcoholism by inducing an acute intolerance to ethanol (drinking alcohol). Disulfiram was reported to inhibit the papain-like protease of MERS and SARS in cell culture, but clinical evidence is lacking <xref rid="b0415" ref-type="bibr">[83]</xref>. It could be effective against SARS-CoV-2, but further investigations are needed.</p></sec><sec id="s0100"><label>8.1.1.6.4</label><title>Other 3CLpro inhibitors and PLP inhibitors</title><p id="p0240">Other 3CLpro inhibitors, such as Cinanserin <xref rid="b0420" ref-type="bibr">[84]</xref>, Flavonoids <xref rid="b0425" ref-type="bibr">[85]</xref>, Cobicistat <xref rid="b0430" ref-type="bibr">[86]</xref>, Atazanavir, Efavirenz, Ritonavir, Dolutegravir <xref rid="b0435" ref-type="bibr">[87]</xref>, Thymopentin, Carfilzomib, Saquinavir <xref rid="b0440" ref-type="bibr">[88]</xref>, Ledipasvir, and Velpatasvir <xref rid="b0445" ref-type="bibr">[89]</xref> and PLP inhibitors, like Diarylheptanoids <xref rid="b0450" ref-type="bibr">[90]</xref>, Grazoprevir, Telaprevir, Boceprevir <xref rid="b0455" ref-type="bibr">[91]</xref>, Darunavir <xref rid="b0460" ref-type="bibr">[92]</xref>, and Formoterol chloroquine <xref rid="b0465" ref-type="bibr">[93]</xref> are other potential approaches to combat SARS-CoV-2, but their efficacy remains to be tested.</p></sec><sec id="s0105"><label>8.1.1.6.5</label><title>Danoprevir</title><p id="p0245">Danoprevir is an NS3/4A protease inhibitor that is used as an anti-HCV drug. It interferes with virus replication and suppresses the effects of the virus on the host response to viral infection. In a small clinical trial of 11 COVID-19 patients, after 4 to 12&#x000a0;days of use of Danoprevir, all the patients recovered <xref rid="b0470" ref-type="bibr">[94]</xref>. So, it might be suggested that Danoprevir could be effective against SARS-CoV-2.</p></sec><sec id="s0110"><label>8.1.1.6.6</label><title>Camostat mesylate</title><p id="p0250">Scientists reported in one study how the spike-like glycoprotein of the SARS-CoV-2 virus binds to the ACE2 receptor. Accordingly, the presence of transmembrane protease serine2 (TMPRSS 2) is required for spike protein priming. The researchers found that Camostat mesylate<italic>,</italic> a serine protease inhibitor, could block the entry of SARS-CoV-2 into lung cells. So, it might be effective against COVID-19. However the application of this drug as a treatment for COVID-19 requires clinical trials <xref rid="b0475" ref-type="bibr">[95]</xref>.</p></sec><sec id="s0115"><label>8.1.1.6.7</label><title>Griffithsin</title><p id="p0255">Griffithsin has antiviral effects against HCV and HIV <italic>in vitro</italic>
<xref rid="b0480" ref-type="bibr">[96]</xref>, <xref rid="b0485" ref-type="bibr">[97]</xref>. It is a red-alga-derived lectin, which binds to oligosaccharides on the surface of various viral glycoproteins, including HIV glycoprotein 120 and SARS-CoV spike glycoprotein <xref rid="b0355" ref-type="bibr">[71]</xref>. Besides, it can inhibit virus entry, reverse transcriptase activity, integrase activity, and protease activity <xref rid="b0490" ref-type="bibr">[98]</xref>. So, it might be effective against SARS-CoV-2, but further investigation is needed.</p></sec></sec><sec id="s0120"><label>8.1.1.7</label><title>Arbidol</title><p id="p0260">Arbidol is a non&#x02010;nucleoside antiviral and immunomodulatory drug for treatment and prevention of influenza, which could be effective against COVID-19 <xref rid="b0495" ref-type="bibr">[99]</xref>. Several clinical trials for investigating its effectiveness against COVID-19 are in progress.</p></sec></sec></sec><sec id="s0125"><label>8.2</label><title>Chloroquine (CQ) and Hydroxychloroquine (HCQ)</title><p id="p0265">CQ is an anti-malarial drug <xref rid="b0500" ref-type="bibr">[100]</xref> with practical activity against SARS-CoV-2 infection <xref rid="b0505" ref-type="bibr">[101]</xref>, which could help in the treatment of COVID-19. It has immunomodulatory effects, such as suppression of the production and release of tumor necrosis factor-&#x003b1; (TNF-&#x003b1;), and Interleukin (IL-6). It also works as a novel type of autophagy inhibitor <xref rid="b0510" ref-type="bibr">[102]</xref>, which probably interferes with viral infection and replication. Moreover, scientists have reported in a number of studies that CQ interferes with the glycosylation of the cellular ACE2 receptor, the spike protein of SARS-CoV, and the entry of the virus <xref rid="b0505" ref-type="bibr">[101]</xref>, <xref rid="b0515" ref-type="bibr">[103]</xref>. Besides, CQ increases the pH of acidic intracellular organelles such as endosomes and lysosomes, which are essential for membrane fusion <xref rid="b0520" ref-type="bibr">[104]</xref>. So, this drug can reduce fever and improve the radiological characteristics of the lungs in COVID-19. Also, it reduced the time to recovery. Besides, CQ is one of three drugs that could be promising for the treatment of new coronavirus disease; the other two drugs, described above, are Favipiravir and Remdesivir <xref rid="b0525" ref-type="bibr">[105]</xref>, where the percentage of patients with a negative viral nucleic acid test was higher with anti-malarial drugs. Until now, no severe side effects have been reported in more than 100 participants treated with CQ in trials. It has been shown that oral absorption of CQ and HCQ in humans is useful in SARS-CoV-2 treatment. Because HCQ was less toxic than CQ in animal models <xref rid="b0530" ref-type="bibr">[106]</xref>, and considering that an overdose of CQ could result in acute poisoning and death <xref rid="b0535" ref-type="bibr">[107]</xref>; the safe dosage (6&#x02013;6.5&#x000a0;mg/kg per day) <xref rid="b0540" ref-type="bibr">[108]</xref> of HCQ sulfate could effectively treat SARS-CoV-2 infections. It must be mentioned that although the combination of HCQ plus Azithromycin c was an effective treatment of COVID-19 <xref rid="b0545" ref-type="bibr">[109]</xref>, the NIH has not recommended it as a routine treatment for clinical use due to the potential for toxicity.</p></sec><sec id="s0130"><label>8.3</label><title>Cytokine-based therapy</title><p id="p0270">The cytokine storm or cytokine release syndrome (CRS) results from the widespread release of pro-inflammatory cytokines following the activation of the immune system by microorganisms or even by therapeutic interventions <xref rid="b0550" ref-type="bibr">[110]</xref>. In SARS-CoV and MERS-CoV infections, overproduction of pro-inflammatory cytokines, such as IL-6, IL-1&#x003b2;, IL-12, IL-18, IL-33, Interferon-&#x003b1; (IFN-&#x003b1;), IFN-&#x003b3;, and TNF-&#x003b1;, or chemokines such as chemokine C-C motif ligand2 (CCL-2), CCL-3, CCL-5, C-X-C motif chemokine ligand 8 (CXCL-8), CXCL-9, and CXCL-10 were included in the cytokine storm <xref rid="b0555" ref-type="bibr">[111]</xref>, <xref rid="b0560" ref-type="bibr">[112]</xref>, <xref rid="b0565" ref-type="bibr">[113]</xref>. It has been shown that by activating type 1 macrophages (M1) and T-helper 1 (Th1) cells, COVID-19 increases the production of inflammatory cytokines like IL-6, IFN-&#x003b3;, and granulocyte monocyte-colony stimulating factor (GM-CSF) <xref rid="b0570" ref-type="bibr">[114]</xref>. It must be mentioned that IL-6 and GM-CSF (can significantly enhance the production of IL-6 by stimulating monocytes <xref rid="b0575" ref-type="bibr">[115]</xref>, <xref rid="b0580" ref-type="bibr">[116]</xref>) which are secreted by monocytes and T cells, are more important in inducing the cytokine storm than other pro-inflammatory cytokines.</p><p id="p0275">The cytokine storm is one of the fundamental causes of COVID-19 pathogenesis, resulting in excessive inflammation, lung damage, ARDS, and other organ failure. Also, the presence of high levels of TNF-&#x003b1;, granulocyte-colony stimulating factor (G-CSF), macrophage inflammatory protein 1A&#x000a0;(MIP-1A), monocyte chemoattractant protein-1 (MCP-1), CXCL-10, IL-10, and IL-7 in severe COVID-19 patients indicates the importance of CRS in the disease progression <xref rid="b0080" ref-type="bibr">[16]</xref>. So, CRS is considered to be a principal cause of death in COVID-19 patients <xref rid="b0585" ref-type="bibr">[117]</xref>, <xref rid="b0590" ref-type="bibr">[118]</xref>.</p><p id="p0280">Therefore, it is important to investigate the control of CRS through various methods like immunomodulation approaches, mesenchymal stem cells (MSCs), or Interferon-based therapy <xref rid="b0595" ref-type="bibr">[119]</xref>.</p><sec id="s0135"><label>8.3.1</label><title>Immunomodulation approaches</title><sec id="s0140"><label>8.3.1.1</label><title>Monoclonal antibodies (mAb)</title><p id="p0285">As mentioned before, IL-6 is an important component of the cytokine storm. So, the use of anti-IL-6 inhibitory agents, like Tocilizumab, Sarilumab, Siltuximab, which are all humanized mAbs, might reduce the adverse effects of CRS <xref rid="b0085" ref-type="bibr">[17]</xref>. It must be noted that anti-GM-CSF mAbs like TJ003234, Gimsilumab, and Lenzilumab are also being evaluated against COVID-19. Moreover, inhibitors of the IL-1 family, IFN-&#x003b3; cytokines, and the Janus kinase&#x000a0;signal transducer and activator of transcription proteins (JAK-STAT) signaling pathway might also be useful for controlling the cytokine storm <xref rid="b0600" ref-type="bibr">[120]</xref>.</p></sec><sec id="s0145"><label>8.3.1.2</label><title>Hyaluronidase and 4-Methylumbelliferone (4-MU)</title><p id="p0290">It has been demonstrated that the increased levels of pro-inflammatory cytokines, including IL-6, IL-1, and TNF-&#x003b1; in the lungs of COVID-19 patients, can result in the production of hyaluronan or hyaluronic acid (HA) by inducing the expression of HA-synthase-2 (HAS2) this may contribute to ARDS and death <xref rid="b0585" ref-type="bibr">[117]</xref>, <xref rid="b0605" ref-type="bibr">[121]</xref>. So, lowering HA levels through administration of hyaluronidase, or 4-methylumbelliferone (4-MU), and blocking the inflammatory cytokines could be effective for treating dyspnea and reducing the mortality rate of COVID-19 patients <xref rid="b0610" ref-type="bibr">[122]</xref>.</p></sec><sec id="s0150"><label>8.3.1.3</label><title>Corticosteroids</title><p id="p0295">Corticosteroids can be useful in controlling CRS, for instance in cancer immunotherapy. Initially, dexamethasone was proposed as an effective agent for managing CRS. However, due to the enhanced risk of vascular necrosis and diabetes (which are mortality risk factors for COVID-19), corticosteroid administration for COVID-19 patients is not recommended <xref rid="b0615" ref-type="bibr">[123]</xref>.</p></sec><sec id="s0155"><label>8.3.1.4</label><title>Immune cell depletion</title><p id="p0300">Immune cells are responsible for the secretion of inflammatory factors. So, decreasing the lymphocyte count might result in CRS suppression. Rituximab, Etoposide, and Lenumab are Mabs used to reduce CD8<sup>+</sup> T cells, decrease the release of interferon-gamma, and to treat CRS and hemophagocytic lymphohistiocytosis (FHLH) <xref rid="b0620" ref-type="bibr">[124]</xref>, <xref rid="b0625" ref-type="bibr">[125]</xref>.</p></sec><sec id="s0160"><label>8.3.1.5</label><title>Interferon-based therapy</title><p id="p0305">Interferons regulate the innate immune system, which is vital for killing viruses by regulating gene transcription <xref rid="b0630" ref-type="bibr">[126]</xref>. IFNs regulate the transcription of genes through activating the JAK-STAT signaling pathway after binding to their receptors on the cell surface. IFN type1 is composed of IFN&#x02010;&#x003b2; and IFN&#x02010;&#x003b1;, and IFN&#x02010;&#x003b1;2b has been shown to rapidly suppress the replication of animal and human coronaviruses <xref rid="b0635" ref-type="bibr">[127]</xref>. SARS-CoV-2 can inhibit the activity of IFN type1 through the suppression of the STAT-1 intracellular signaling pathway <xref rid="b0640" ref-type="bibr">[128]</xref>. So, IFN-based therapies could be useful for treating COVID-19.</p><p id="p0310">Interestingly, the low morbidity and mortality rates of COVID-19 in children might be due to the low secretion threshold of IFNs in children, and the rapid production of IFNs after infection. Thus, the high secretion threshold of IFNs in adults could be responsible for the higher mortality rate in these patients. So, IFN-based therapies might be effective against COVID-19, especially in the early phase of the disease <xref rid="b0640" ref-type="bibr">[128]</xref>.</p><p id="p0315">In addition to the direct suppression of the SARS-CoV-2, which could contribute to the therapeutic response, IFN-based therapy can stimulate the innate immune. So, pegylated IFN&#x003b1;-2a and IFN&#x003b1;-2b could be tested in patients with COVID-19, as they stimulate innate antiviral responses.</p><p id="p0320">Nevertheless, clinicians must be wary of administering IFNs alone, due to the possibility of increasing the cytokine storm with high doses of IFNs.</p></sec><sec id="s0165"><label>8.3.1.6</label><title>Stem-cell therapy</title><p id="p0325">Stem-cell therapy has demonstrated a possible therapeutic benefit in almost all incurable diseases <xref rid="b0640" ref-type="bibr">[128]</xref>. Among stem cells, MSCs have received most attention because of their many advantages. These include, a high proliferation rate, self-renewal ability, reparative properties, availability from different tissues, multidirectional differentiation, lack of adverse reactions, and long-term storage ability. In addition to tissue regeneration, they are used for their anti-inflammatory and immunoregulatory activity <xref rid="b0645" ref-type="bibr">[129]</xref>. Chinese scientists have reported the use of MSCs as an anti-inflammatory approach to cytokine storm-like disorders. So, they could be effective in controlling CRS.</p><p id="p0330">MSCs based immunomodulatory activities include suppressing the over-activation of T cells and macrophages</p><p id="p0335">stimulating the anti-inflammatory macrophage 2 phenotype (M2)</p><p id="p0340">stimulating T-regs</p><p id="p0345">and suppressing pro-inflammatory cytokines. MSC-based therapy might decrease the risk of CRS in COVID-19 patients by reducing the production of TNF-&#x003b1;, IFN-&#x003b1;, IL-1, IL-6, and IL-12 <xref rid="b0650" ref-type="bibr">[130]</xref>.</p><p id="p0350">Moreover, MSCs might improve ARDS, regenerate lung tissue, and lessen lung fibrosis through secreting IL-10, vascular endothelial growth factor (VEGF), keratinocyte growth factor (KGF), and hepatocyte growth factor (HGF) in SARS-CoV-2 patients <xref rid="b0650" ref-type="bibr">[130]</xref>. It is possible that MSC-based therapy could remove the need for ventilation in COVID-19 patients, return the T cell counts to a normal range, restore pulmonary function, decrease the level of inflammatory cytokines, and increase the level of anti-inflammatory cytokines <xref rid="b0655" ref-type="bibr">[131]</xref>, <xref rid="b0660" ref-type="bibr">[132]</xref>.</p><p id="p0355">In order to improve the effectiveness of MSC-induced anti-inflammatory response, they could be pretreated using IFN-&#x003b3;, which is low or absent in severe COVID-19 <xref rid="b0665" ref-type="bibr">[133]</xref>.</p><p id="p0360">These cytokine-licensed MSCs could be more effective in the suppression of hyperactive immune response and promotion of tissue repair, because it is known that cytokine-licensed MSCs were effective in preventing lipopolysaccharide (LPS)-induced acute lung damage <xref rid="b0670" ref-type="bibr">[134]</xref>. So, several clinical trials are being carried out for evaluating the effectiveness of MSCs against COVID-19.</p></sec></sec></sec><sec id="s0170"><label>8.4</label><title>Passive antibody therapy and convalescent plasma therapy</title><p id="p0365">Plasma antibodies contribute to the elimination of infection via directly binding to pathogens and neutralizing them, or by activating indirect immune responses, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity, or phagocytosis <xref rid="b0675" ref-type="bibr">[135]</xref>, <xref rid="b0680" ref-type="bibr">[136]</xref>. In COVID-19 patients, their plasma contains active specific neutralizing antibodies (which mediate the anti-infective function of plasma therapy) and non-neutralizing antibodies (which might boost prophylaxis and improvement of patients).</p><p id="p0370">Hyper-immune immunoglobulin therapy or convalescent plasma (CP) is a passive-adaptive-immunotherapy applied to protect individuals from clinical infection or prevent disease development. The early administration of CP or hyper-immune immunoglobulin that contains high antibody titers could decrease the viral load, reduce disease mortality, and shorten hospital stays <xref rid="b0685" ref-type="bibr">[137]</xref>, <xref rid="b0690" ref-type="bibr">[138]</xref>.</p><p id="p0375">While passive antibody therapy involves the pooling of immunoglobulin preparations with high antibody titers, plasma therapy is applied as an emergency treatment, especially in epidemics and pandemics, when there is limited time or resources for pooled immunoglobulin preparation. Compared to passive antibody therapy which generates short-term rapid immunity, persistant immunity is produced by monoclonal antibodies or hyper-immune globulin (fractionated plasma products) <xref rid="b0695" ref-type="bibr">[139]</xref>. Therefore, convalescent plasma is employed as a rapid immune-based therapy in the early stages of the disease <xref rid="b0700" ref-type="bibr">[140]</xref>, to increase infected patients immunity against the virus, stop COVID-19 progression, and enhance the therapeutic success rate <xref rid="b0705" ref-type="bibr">[141]</xref>. Moreover, plasma therapy can decrease viremia and reduce new infections (through neutralizing antibodies), clear free virus and infected cells, and alleviate the symptoms (like dry cough, fever, sputum, muscle pain) and pulmonary damage. Moreover, it can increase the lymphocyte ratio and blood oxygen saturation without any adverse effects <xref rid="b0705" ref-type="bibr">[141]</xref>, <xref rid="b0710" ref-type="bibr">[142]</xref>, <xref rid="b0715" ref-type="bibr">[143]</xref>, <xref rid="b0720" ref-type="bibr">[144]</xref>.</p><p id="p0380">The FDA has approved the administration of convalescent plasma containing specific antibodies against SARS-CoV-2 <xref rid="b0725" ref-type="bibr">[145]</xref>. Besides, the FDA has recommended that people who have recovered from COVID-19 (for at least two weeks) should donate their plasma to help other patients. It is estimated that each donation can provide sufficient plasma for four patients <xref rid="b0730" ref-type="bibr">[146]</xref>.</p><p id="p0385">However, there are some challenges in the collection of plasma from donor serum during the recovery period or after recovery, and confirming the proper level of neutralizing antibody titer. Some of these challenges are the availability of willing qualified donors, clinical conditions, eliminating host interactions, and the viral kinetics of SARS-CoV-2, that will need to be solved before convalescent plasma can become a generalized therapeutic option.</p><p id="p0390">A qualified donor must be selected based on a confirmed history of COVID-19 infection, including a negative follow-up molecular test, the absence of symptoms, normal physical examination, and pre-donation screening assays. It should be mentioned that since plasma with a high neutralizing antibody titer is only obtained at 14&#x000a0;days after the resolution of symptoms, this is the best time to harvest the plasma <xref rid="b0715" ref-type="bibr">[143]</xref>. Besides, it has been suggested that apheresis might be better for optimizing the convalescent plasma product, rather than whole blood donation. The appropriate dose convalescent plasma therapy in COVID-19 was determined based on past experience of applying plasma therapy in SARS-CoV, which was 5&#x000a0;mL/kg of plasma with&#x000a0;&#x02265;&#x000a0;1:160 titer <xref rid="b0700" ref-type="bibr">[140]</xref>.</p><p id="p0395">It must be taken into account that transfusion-transmitted SARS-CoV-2, acute transfusion-related injuries, other transfusion-transmissible infections, transfusion-associated circulatory overload, and allergic transfusion reactions could be risks of plasma therapy in the treatment of COVID-19 <xref rid="b0735" ref-type="bibr">[147]</xref>, <xref rid="b0740" ref-type="bibr">[148]</xref>.</p><p id="p0400">It must be mentioned that in some patients, COVID-19 antibodies are not always found after recovery, which suggests that some patients recover without antibodies <xref rid="b0745" ref-type="bibr">[149]</xref> or else the antibodies vanish after recovery. Although one study evaluated the effectiveness of plasma therapy in five patients (who were mechanically ventilated and received methylprednisolone) all of them showed a reduction in COVID-19 symptoms and viral load, it is not yet clear that the antibodies from donors are active and effective or not <xref rid="b0750" ref-type="bibr">[150]</xref>.</p><p id="p0405">Even considering the risks of plasma therapy, it could still be effective as an emergency COVID-19 treatment.</p></sec><sec id="s0175"><label>8.5</label><title>Monoclonal antibodies (mAbs)</title><p id="p0410">Monoclonal antibodies (mAbs) can be obtained from COVID-19 patients or by laboratory preparation. They are characterized by high specificity and purity, high safety, and a low rate of blood-borne infections that can overcome the limitations of intravenous immunoglobulins and convalescent plasma therapy. mAbs can be chosen to target the specific epitopes of surface SARS-CoV-2 proteins and could inhibit the virus entry into host cells (including receptor binding, membrane fusion, and sialic acid-binding sites), and reduce replication and infection progression.</p><p id="p0415">Some mAbs that target the spike protein in SARS-CoV and MERS-CoV have shown promising results <italic>in vitro</italic> and <italic>in vivo,</italic> that could be potentially useful against SARS-CoV-2 <xref rid="b0755" ref-type="bibr">[151]</xref>. For example, specific neutralizing mAbs against the receptor-binding domain (RBD) in spike protein (CR3014 <xref rid="b0760" ref-type="bibr">[152]</xref>, CR3022 <xref rid="b0765" ref-type="bibr">[153]</xref>, 311mab&#x02013;31B5, 311mab&#x02013;32D4, and 311mab&#x02013;31B9), or specific mAbs that bind to ACE2 could all effectively block virus entry <xref rid="b0695" ref-type="bibr">[139]</xref>. It must be mentioned that contrary to 311mab&#x02013;31B9 (without any neutralization capability) <xref rid="b0770" ref-type="bibr">[154]</xref>, 311mab-31B5 and 311mab-32D4 can both potently suppress the SARS-CoV-2 RBD protein and interaction with the human ACE2 (hACE2) protein, leading to virus neutralization. Moreover, using CR3022 as a monotherapy, or else in combination with other drugs might result in COVID-19 patient improvement. Besides, 47D11 could powerfully suppress the infection of SARS-CoV and SARS-CoV-2 through an unknown mechanism <xref rid="b0775" ref-type="bibr">[155]</xref>.</p><p id="p0420">Furthermore, m396, CR3014 <xref rid="b0780" ref-type="bibr">[156]</xref>, and Meplazumab (which is an anti-CD147 Mab <xref rid="b0785" ref-type="bibr">[157]</xref>, could be alternative monoclonal antibodies to be used against SARS-CoV-2 <xref rid="b0765" ref-type="bibr">[153]</xref>. So, mAbs can be considered as potential therapeutic options against COVID-19.</p></sec><sec id="s0180"><label>8.6</label><title>Polyclonal antibodies</title><p id="p0425">Polyclonal antibodies can be used as prophylactic or therapeutic agents against viral infections <xref rid="b0375" ref-type="bibr">[75]</xref>. For example, SAB-301 is a well-tolerated antiviral treatment for MERS-CoV <xref rid="b0790" ref-type="bibr">[158]</xref>. So, polyclonal antibodies might also be effective against COVID-19.</p></sec><sec id="s0185"><label>8.7</label><title>Intravenous immunoglobulin (IVIg)</title><p id="p0430">IVIg is an effective immunomodulatory agent, which has been applied in autoimmune and inflammatory diseases, bacterial infections, severe viral infections, fungal infections, and also in graft versus host disease (GVHD). It is composed of polyclonal immunoglobulin G or IgG. IVIg can modulate the immune system through various mechanisms, like reducing and preventing the production of cytokines, enhancing anti-inflammatory cytokines, and inducing immune system responses against the virus <xref rid="b0795" ref-type="bibr">[159]</xref>. IVIg has been used to treat infections of the upper and lower respiratory tracts <xref rid="b0800" ref-type="bibr">[160]</xref>, <xref rid="b0805" ref-type="bibr">[161]</xref>. Besides, IVIg therapy showed a clinical benefit and good tolerability in SARS and MERS cases <xref rid="b0810" ref-type="bibr">[162]</xref>, <xref rid="b0815" ref-type="bibr">[163]</xref>. So, IVIg therapy could be a potential therapeutic option against COVID-19 <xref rid="b0295" ref-type="bibr">[59]</xref>. High-dose IVIg therapy, 0.3&#x02013;0.5&#x000a0;g per kg body weight over five days, has been proposed for COVID-19 patients. Scientists have shown that the application of high-dose IVIg at the appropriate time point could prevent disease progression to a severe state and enhance the patient recovery rate in early phases of the disease. Moreover, after administration of IVIg no adverse effects were reported <xref rid="b0820" ref-type="bibr">[164]</xref>. So, immunotherapy with IVIg either alone or in combination with other anti-SARS-CoV-2 therapies could be an alternative option for COVID-19 patients.</p></sec><sec id="s0190"><label>8.8</label><title>Anakinra</title><p id="p0435">In one small retrospective cohort study in Italy, the effect of Anakinra, a recombinant Interleukin-1 receptor antagonist, was studied in the treatment of COVID-19. In this study, 29 patients received the drug, while 16 patients received only standard treatment for COVID-19. Twenty-one patients (72%) of the intervention group had a CRP level below the standard after 21&#x000a0;days, and most of them recovered; while five patients were mechanically ventilated, and three died. Only eight (50%) of the 16 control patients had improved respiratory status after 21&#x000a0;days, of which one person was mechanically ventilated, and seven died. Survival rates at 21&#x000a0;days in the intervention and control groups were 90% and 56%, respectively with a significant difference. Anakinra could increase the survival of patients with COVID-19 and improve respiratory status, and may be an effective treatment <xref rid="b0825" ref-type="bibr">[165]</xref>.</p></sec><sec id="s0195"><label>8.9</label><title>Ibuprofen</title><p id="p0440">Ibuprofen has shown problems with safety <xref rid="b0830" ref-type="bibr">[166]</xref>. Discussions over the safety of non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of COVID-19 has involved the European Medicines Agency. It had been proposed that NSAIDs could be considered for treating the emerging viral illness in some cases, but most patients with COVID-19 symptoms should use Paracetamol rather than Ibuprofen, because the latter could worsen the condition. Reports in French media showed a deterioration in the condition of four young people with COVID-19 after taking Ibuprofen <xref rid="b0835" ref-type="bibr">[167]</xref>
<italic>.</italic> So, it is wise to use Paracetamol instead of Ibuprofen for COVID-19 patients.</p></sec><sec id="s0200"><label>8.10</label><title>Angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin receptor blocker (ARB)</title><p id="p0445">It had been suggested that the use of ACE-I and ARB drugs for cardiovascular indications could lead to an up-regulation of ACE2 receptors, and hence the development of more severe COVID-19 <xref rid="b0840" ref-type="bibr">[168]</xref>. However, the European Heart Association as well as three major American cardiology bodies, including the American Heart Association, the American College of Cardiology, and the Heart Failure Society of America, have all emphasized that patients who have been taking ACE-I or ARB drugs should continue their treatment.</p></sec><sec id="s0205"><label>8.11</label><title>Human recombinant solution ACE2 (hrsACE2)</title><p id="p0450">The hrsACE2 solution, previously clinically tested in phase one and two clinical trials (2017), could significantly inhibit COVID-19 infection in the early stage and prevent the virus from attaching to the cell. It reduced SARS-CoV-2 levels in Vero-E6 cells (cells used for virus isolation) up to 1000&#x02013;5000 times (in terms of viral load) in laboratory studies <xref rid="b0845" ref-type="bibr">[169]</xref>. It must be mentioned that this study had some limitations, for example, lung organoids were not tested, and the experiment only simulated the early stages of COVID-19. So, because SARS-CoV-2 can directly infect human blood vessels and enter the kidneys, and hrsACE2 could prevent this occurrence, it might be used in the clinic. However, further investigations are needed.</p></sec><sec id="s0210"><label>8.12</label><title>CRISPR Cas13</title><p id="p0455">Clustered regularly interspaced short palindromic repeats (CRISPR) is a novel genome engineering tool, which is composed of two components, including a guide RNA (gRNA), which is specific to the target DNA or RNA sequence, and a non-specific CRISPR associated endonuclease protein or Cas protein.</p><p id="p0460">CRISPR Cas13 is a type VI CRISPR-associated RNA-guided ribonuclease, which targets a specific sequence of RNA. Three protein families have been recognized, including Cas13a (formerly known as C2c2), Cas13b, and Cas13c <xref rid="b0850" ref-type="bibr">[170]</xref>, <xref rid="b0855" ref-type="bibr">[171]</xref>. Cas13a enzymes can also be a suitable tool for nucleic acid sequence detection <xref rid="b0860" ref-type="bibr">[172]</xref>. In addition, since Cas13 and inactive Cas13 target specific RNA sites for cleavage and inhibition, respectively, they could be used as an effective COVID-19 therapy. However, further investigations are essential.</p></sec><sec id="s0215"><label>8.13</label><title>Nitric oxide</title><p id="p0465">Newborns with severe ARDS, are treated with high&#x02010;dose pulmonary surfactant, inhaled nitric oxide, high&#x02010;frequency oscillatory ventilation, and extracorporeal membrane oxygenation. This approach might be effective for patients of COVID-19 with ARDS <xref rid="b0865" ref-type="bibr">[173]</xref>, <xref rid="b0870" ref-type="bibr">[174]</xref> as well.</p></sec><sec id="s0220"><label>8.14</label><title>Oxygen therapy</title><p id="p0470">Almost all patients are administered oxygen therapy, and WHO has recommended extracorporeal membrane oxygenation (ECMO) for patients with refractory hypoxemia <xref rid="b0875" ref-type="bibr">[175]</xref>.</p></sec><sec id="s0225"><label>8.15</label><title>Lithium</title><p id="p0475">Because lithium reduces apoptosis and inhibits glycogen synthase kinase3 beta (GSK-3&#x003b2;), which interacts with receptors and triggers signal transduction events, it might be effective against COVID-19 <xref rid="b0880" ref-type="bibr">[176]</xref>.</p></sec><sec id="s0230"><label>8.16</label><title>Antibiotics</title><p id="p0480">Antibioticshave been suggested for alleviating the pneumonitis symptoms, and it was shown in an <italic>in vitro</italic> study that Teicoplanin could prevent the entry of SARS-CoV-2 into the cytoplasm <xref rid="b0885" ref-type="bibr">[177]</xref>. Moreover, Azithromycin has shown some success against COVID-19.</p></sec><sec id="s0235"><label>8.17</label><title>Ivermectin</title><p id="p0485">Ivermectin is an FDA-approved drug for the treatment of parasitic amnesia, which is widely available. It was shown in one study that adding five &#x003bc;M of Ivermectin to virus-infected Vero/hSLAM cells reduced the levels of viral RNA by 5,000 times after 48-hour culture <xref rid="b0890" ref-type="bibr">[178]</xref>. So, it could be effective against COVID-19.</p></sec><sec id="s0240"><label>8.18</label><title>Nitazoxanide</title><p id="p0490">Nitazoxanide is an antidiarrheal drug that has been proposed to inhibit 2019-nCoV <xref rid="b0345" ref-type="bibr">[69]</xref>, but more investigation is needed. Besides, the combination of Nitazoxanide and Azithromycin could be more effective than using them as single agents against COVID-19 <xref rid="b0895" ref-type="bibr">[179]</xref>. Nevertheless, combining several therapies may increase the side effects and lead to drug-drug interactions, which must be taken into account when proposing new treatments for COVID-19.</p></sec><sec id="s0245"><label>8.19</label><title>Bacillus Calmette&#x02013;Gu&#x000e9;rin (BCG)</title><p id="p0495">Bacillus Calmette&#x02013;Gu&#x000e9;rin (BCG) vaccination is being considered in clinical trials to test its efficacy to decrease COVID-19 morbidity and mortality rates <xref rid="b0895" ref-type="bibr">[179]</xref>.</p></sec><sec id="s0250"><label>8.20</label><title>Colchicine</title><p id="p0500">Colchicine has an immunomodulatory effect, and is commonly used in the treatment of gout. Due to its immunomodulatory effects, it could be useful for ameliorating the clinical manifestations of COVID-19 <xref rid="b0900" ref-type="bibr">[180]</xref>.</p><p id="p0505">Because of the wide variety of therapeutic options either as a single drug or in combination with other drugs, it is difficult for clinical trials to be conclusive. This is why WHO is conducting the Solidarity clinical trial; up to April 21st, 2020, over 100 countries have joined this clinical trial to defeat SARS-CoV-2. <xref rid="b0905" ref-type="bibr">[181]</xref>.</p></sec><sec id="s0255"><label>8.21</label><title>Vitamins</title><p id="p0510">It has been demonstrated in several studies that vitamin B3 (niacin or nicotinamide) was effective in reducing injury in animal models with bleomycin-induced lung damage <xref rid="b0910" ref-type="bibr">[182]</xref>. Vitamin C could also be effective in preventing COVID-19 as it can reduce the severity of lower respiratory tract infections <xref rid="b0915" ref-type="bibr">[183]</xref>. Moreover, It was suggested that the supplementation with vitamin D and vitamin E might increase resistance to SARS-CoV-2 <xref rid="b0920" ref-type="bibr">[184]</xref>. Thus, vitamin supplements might be worth combining with other therapies in patients with COVID-19.</p></sec></sec><sec id="s0260"><label>9</label><title>Clinical trials</title><p id="p0515">At the time of the preparation of this study (March 29th, 2020), more than 200 clinical trials of COVID-19 had been listed in <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/" id="ir005"><underline>https://clinicaltrials.gov/</underline></ext-link>. Trials involving vaccines, antiviral drugs, immunotherapies, monoclonal antibodies, stem cells, and nitric oxide are summarized in <xref rid="t0005" ref-type="table">Table 1</xref>
.<table-wrap position="float" id="t0005"><label>Table 1</label><caption><p>Clinical trials for evaluating preventive and therapeutic options against SARS-CoV-2 (up to March 29th 2020).</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Clinical trials</th><th>Identifier</th><th>Status</th><th>country</th></tr></thead><tbody><tr><td>Tocilizumab in&#x000a0;COVID-19&#x000a0;Pneumonia</td><td>NCT04317092</td><td>Recruiting</td><td>Italy</td></tr><tr><td>Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With&#x000a0;COVID-19</td><td>NCT04315298</td><td>Recruiting</td><td>United States</td></tr><tr><td>A Pilot Study of Sildenafil in&#x000a0;COVID-19</td><td>NCT04304313</td><td>Recruiting</td><td>China</td></tr><tr><td>ACE Inhibitors, Angiotensin II Type-I Receptor Blockers, and Severity of COVID-19 (CODIV-ACE)</td><td>NCT04318418</td><td>Not yet recruiting</td><td>Italy</td></tr><tr><td>Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention (HCQ4COV19)</td><td>NCT04304053</td><td>Recruiting</td><td>Spain</td></tr><tr><td>The Use PUL-042 Inhalation Solution to Prevent COVID-19 in Adults Exposed to SARS-CoV-2</td><td>NCT04313023</td><td>Not yet recruiting</td><td/></tr><tr><td>The Use of Angiotensin-Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?</td><td>NCT04322786</td><td>Not yet recruiting</td><td/></tr><tr><td>Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.</td><td>NCT04290871</td><td>Withdrawn</td><td/></tr><tr><td>Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID-19</td><td>NCT04322396</td><td>Not yet recruiting</td><td/></tr><tr><td>Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool</td><td>NCT04274322</td><td>Not yet recruiting</td><td/></tr><tr><td>Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI</td><td>NCT04324073</td><td>Not yet recruiting</td><td>France</td></tr><tr><td>Hydroxychloroquine Versus Placebo in Patients Presenting COVID-19 Infection and at Risk of Secondary Complication: a Prospective, Multicentre, Randomised, Double-blind Study</td><td>NCT04325893</td><td>Not yet recruiting</td><td/></tr><tr><td>Efficacy and Safety of IFN-&#x003b1;2&#x003b2; in the Treatment of Novel Coronavirus Patients</td><td>NCT04293887</td><td>Not yet recruiting</td><td/></tr><tr><td>Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia</td><td>NCT04275388</td><td>Not yet recruiting</td><td/></tr><tr><td>Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2</td><td>NCT04323527</td><td>Recruiting</td><td>Brazil</td></tr><tr><td>Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection</td><td>NCT04283461</td><td>Recruiting</td><td>United States</td></tr><tr><td>Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)</td><td>NCT04322682</td><td>Recruiting</td><td>Canada</td></tr><tr><td>Tocilizumab for SARS-CoV2 Severe Pneumonitis</td><td>NCT04315480</td><td>Not yet recruiting</td><td>Italy</td></tr><tr><td>Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV</td><td>NCT04252274</td><td>Recruiting</td><td>China</td></tr><tr><td>Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection</td><td>NCT04251871</td><td>Recruiting</td><td>China</td></tr><tr><td>COVIDL1: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection</td><td>NCT04326426</td><td>Not yet recruiting</td><td/></tr><tr><td>Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19</td><td>NCT04306393</td><td>Recruiting</td><td>United States</td></tr><tr><td>Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections</td><td>NCT03331445</td><td>Active, not recruiting</td><td>Canada</td></tr><tr><td>NK Cells Treatment for Novel Coronavirus Pneumonia</td><td>NCT04280224</td><td>Recruiting</td><td>China</td></tr><tr><td>Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection</td><td>NCT04261907</td><td>Not yet recruiting</td><td/></tr><tr><td>A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia</td><td>NCT04276987</td><td>Not yet recruiting</td><td/></tr><tr><td>Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2</td><td>NCT04308668</td><td>Recruiting</td><td>United States</td></tr><tr><td>STOP PIV - Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects</td><td>NCT03808922</td><td>Recruiting</td><td>United States</td></tr><tr><td>Norwegian Coronavirus Disease 2019 Study</td><td>NCT04316377</td><td>Not yet recruiting</td><td/></tr><tr><td>Lessening Organ Dysfunction With VITamin C</td><td>NCT03680274</td><td>Recruiting</td><td>Canada</td></tr><tr><td>Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory Failure</td><td>NCT04244591</td><td>Recruiting</td><td>China</td></tr><tr><td>Convalescent Plasma to Limit Coronavirus Associated Complications</td><td>NCT04325672</td><td>Not yet recruiting</td><td>United States</td></tr><tr><td>Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia</td><td>NCT04264533</td><td>Recruiting</td><td>China</td></tr><tr><td>Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure Drug: RoActemra iv, RoActemra sc, Kevzara sc</td><td>NCT04322773</td><td>Not yet recruiting</td><td>Denmark</td></tr><tr><td>Safety and Efficacy of Hydroxychloroquine Associated With Azythromycin in SARS-Cov-2 Virus</td><td>NCT04322123</td><td>Not yet recruiting</td><td>Brazil</td></tr><tr><td>Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)</td><td>NCT04307693</td><td>Recruiting</td><td>Korea</td></tr><tr><td>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734&#x02122;) in Participants With Severe Coronavirus Disease (COVID-19)</td><td>NCT04292899</td><td>Recruiting</td><td>United States</td></tr><tr><td>NestCell&#x000ae; Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia (HOPE)</td><td>NCT04315987</td><td>Not yet recruiting</td><td/></tr><tr><td>Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT (BEST-RCT)</td><td>NCT04305106</td><td>Recruiting</td><td>China</td></tr><tr><td>The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia</td><td>NCT04273529</td><td>Not yet recruiting</td><td/></tr><tr><td>The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19</td><td>NCT04273581</td><td>Not yet recruiting</td><td/></tr><tr><td>Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells</td><td>NCT04313322</td><td>Recruiting</td><td>Jordan</td></tr><tr><td>Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial) (HYDRA)</td><td>NCT04315896</td><td>Not yet recruiting</td><td/></tr><tr><td>Tetrandrine Tablets Used in the Treatment of COVID-19 (TT-NPC)</td><td>NCT04308317</td><td>Enrolling by invitation</td><td>China</td></tr><tr><td>Fingolimod in COVID-19</td><td>NCT04280588</td><td>Recruiting</td><td>China</td></tr><tr><td>CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment (SAC-COVID)v</td><td>NCT04317040</td><td>Not yet recruiting</td><td>United States</td></tr><tr><td>Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)</td><td>NCT04288102</td><td>Recruiting</td><td>China</td></tr><tr><td>The Clinical Study of Carrimycin on Treatment Patients With COVID-19</td><td>NCT04286503</td><td>Not yet recruiting</td><td/></tr><tr><td>Efficacy and Safety of Corticosteroids in COVID-19(Methylprednisolone)</td><td>NCT04273321</td><td>Recruiting</td><td>China</td></tr><tr><td>Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)</td><td>NCT04318444</td><td>Not yet recruiting</td><td>United States</td></tr><tr><td>Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial) (PHYDRA)</td><td>NCT04318015</td><td>Not yet recruiting</td><td/></tr><tr><td>Safety and Immunity of Covid-19 aAPC Vaccine</td><td>NCT04299724</td><td>Recruiting</td><td>China</td></tr><tr><td>Immunity and Safety of Covid-19 Synthetic Minigene Vaccine</td><td>NCT04276896</td><td>Recruiting</td><td>China</td></tr><tr><td>A Phase I Clinical Trial in 18&#x02013;60 Adults (APICTH)(vaccine)</td><td>NCT04313127</td><td>Recruiting</td><td>China</td></tr><tr><td>Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019</td><td>NCT04310228</td><td>Recruiting</td><td>China</td></tr><tr><td>Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells</td><td>NCT04302519</td><td>Not yet recruiting</td><td/></tr><tr><td>Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)</td><td>NCT04295551</td><td>Not yet recruiting</td><td/></tr><tr><td>Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting (COPCOV)</td><td>NCT04303507</td><td>Not yet recruiting</td><td/></tr><tr><td>Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)</td><td>NCT04273763</td><td>Enrolling by invitation</td><td>China</td></tr><tr><td>Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19</td><td>NCT04278963</td><td>Active, not recruiting</td><td>China</td></tr><tr><td>Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Chloroquine for Treatment of COVID19: A Randomized Control Trial (THDMS-COVID19)</td><td>NCT04303299</td><td>Not yet recruiting</td><td>Thailand</td></tr><tr><td>The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19</td><td>NCT04285190</td><td>Not yet recruiting</td><td/></tr><tr><td>Immunoregulatory Therapy for 2019-nCoV: PD-1 blocking antibody&#x000a0;+&#x000a0;standard treatment, Thymosin&#x000a0;+&#x000a0;standard treatment, standard treatment</td><td>NCT04268537</td><td>Not yet recruiting</td><td/></tr><tr><td>Tocilizumab vs. CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19 (TACOS)</td><td>NCT04306705</td><td>Recruiting</td><td>China</td></tr><tr><td>Mild/Moderate 2019-nCoV Remdesivir RCT</td><td>NCT04252664</td><td>Recruiting</td><td>China</td></tr><tr><td>Losartan for Patients With COVID-19 Requiring Hospitalization</td><td>NCT04312009</td><td>Not yet recruiting</td><td>United States</td></tr><tr><td>Trial of Treatments for COVID-19 in Hospitalized Adults (DisCoVeRy)<break/>Drug: Remdesivir, Lopinavir/ritonavir, Interferon Beta-1A, Standard of care</td><td>NCT04315948</td><td>Not yet recruiting</td><td/></tr><tr><td>Losartan for Patients With COVID-19 Not Requiring Hospitalization</td><td>NCT04311177</td><td>Not yet recruiting</td><td>United States</td></tr><tr><td>Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia</td><td>NCT04273646</td><td>Not yet recruiting</td><td>China</td></tr><tr><td>Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus</td><td>NCT04252118</td><td>Recruiting</td><td>China</td></tr><tr><td>The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia</td><td>NCT04261426</td><td>Not yet recruiting</td><td/></tr><tr><td>A Prospective/Retrospective, Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia<break/>Drug: Abidol hydrochloride, Oseltamivir, Lopinavir/ritonavir</td><td>NCT04255017</td><td>recruiting</td><td>China</td></tr><tr><td>A Prospective/Retrospective, Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia<break/>Drug: Abidol hydrochloride, Abidol Hydrochloride combined with Interferon atomization</td><td>NCT04254874</td><td>recruiting</td><td>China</td></tr><tr><td>Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP)</td><td>NCT04275414</td><td>recruiting</td><td>China</td></tr><tr><td>A Randomized, Open, Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia</td><td>NCT04261270</td><td>recruiting</td><td>China</td></tr><tr><td>Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress (COVID-AIV)</td><td>NCT04311697</td><td>Not yet recruiting</td><td>Israel</td></tr><tr><td>The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia<break/>Drug: Methylprednisolone</td><td>NCT04263402</td><td>recruiting</td><td>China</td></tr><tr><td>Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19 (NoCovid)</td><td>NCT04305457</td><td>Recruiting</td><td>United States</td></tr><tr><td>Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. (BARI-COVID)</td><td>NCT04320277</td><td>Recruiting</td><td>Italy</td></tr><tr><td>Adaptive COVID-19 Treatment Trial (ACTT)<break/>Drug: Remdesivir</td><td>NCT04280705</td><td>Recruiting</td><td>United States</td></tr><tr><td>Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu<break/>Drug: N-acetylcysteine&#x000a0;+&#x000a0;Fuzheng Huayu Tablet, N-acetylcysteine&#x000a0;+&#x000a0;Placebo</td><td>NCT04279197</td><td>Recruiting</td><td>China</td></tr><tr><td>NO Prevention of COVID-19 for Healthcare Providers<break/>Drug: Inhaled nitric oxide gas</td><td>NCT04312243</td><td>Not yet recruiting</td><td/></tr><tr><td>Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients<break/>Drug: Immunoglobulin of cured patients, &#x003b3;-Globulin</td><td>NCT04264858</td><td>Not yet recruiting</td><td>China</td></tr><tr><td>Efficacy and Safety of IFN-&#x003b1;2&#x003b2; in the Treatment of Novel Coronavirus Patients<break/>Drug: Recombinant human interferon &#x003b1;1&#x003b2;</td><td>NCT04293887</td><td>Not yet recruiting</td><td/></tr><tr><td>Experimental Trial of rhIFN&#x003b1; Nasal Drops to Prevent 2019-nCOV in Medical Staff<break/>Drug: recombinant human Interferon Alpha-1b, thymosin alpha 1</td><td>NCT04320238</td><td>Recruiting</td><td>China</td></tr><tr><td>Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19</td><td>NCT04292340</td><td>Recruiting</td><td>China</td></tr><tr><td>Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus</td><td>NCT04260594</td><td>Not yet recruiting</td><td/></tr><tr><td>Evaluation of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of Novel Coronavirus Infection<break/>Drug: Ganovo&#x000a0;+&#x000a0;ritonavir+/-Interferon nebulization</td><td>NCT04291729</td><td>Completed</td><td>China</td></tr><tr><td>Eculizumab (Soliris) in Covid-19 Infected Patients</td><td>NCT04288713</td><td>Available</td><td/></tr><tr><td>Severe 2019-nCoV Remdesivir RCT</td><td>NCT04257656</td><td>Recruiting</td><td>China</td></tr><tr><td>nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19</td><td>NCT04306393</td><td>Recruiting</td><td>United States</td></tr><tr><td>Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(CoV) Pneumonia</td><td>NCT04269525</td><td>Recruiting</td><td>China</td></tr><tr><td>Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection</td><td>NCT04261907</td><td>Not yet recruiting</td><td/></tr><tr><td>Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia</td><td>NCT04264533</td><td>Recruiting</td><td>China</td></tr><tr><td>Expanded Access Remdesivir (RDV; GS-5734&#x02122;)</td><td>NCT04302766</td><td>Available</td><td/></tr><tr><td>Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia</td><td>NCT04275388</td><td>Not yet recruiting</td><td/></tr><tr><td>Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2 Infection</td><td>NCT04283461</td><td>recruiting</td><td>United States</td></tr><tr><td>Tocilizumab for SARS-CoV2 Severe Pneumonitis</td><td>NCT04315480</td><td>Not yet recruiting</td><td>Italy</td></tr><tr><td>Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV</td><td>NCT04252274</td><td>recruiting</td><td>China</td></tr><tr><td>Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV (HC-nCoV)</td><td>NCT04261517</td><td>Completed</td><td>China</td></tr><tr><td>Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection<break/>Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules, Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)</td><td>NCT04251871</td><td>recruiting</td><td>China</td></tr><tr><td>Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia</td><td>NCT04275245</td><td>recruiting</td><td>China</td></tr><tr><td>Stem Cell Educator Therapy Treat the Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2</td><td>NCT04299152</td><td>Not yet recruiting</td><td/></tr><tr><td>NK Cells Treatment for Novel Coronavirus Pneumonia</td><td>NCT04280224</td><td>Recruiting</td><td>China</td></tr><tr><td>Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory Failure<break/>Drug: methylprednisolone therapy</td><td>NCT04244591</td><td>Recruiting</td><td>China</td></tr><tr><td>Norwegian Coronavirus Disease 2019 Study<break/>Drug: Hydroxychloroquine Sulfate</td><td>NCT04316377</td><td>Not yet recruiting</td><td/></tr><tr><td>Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment</td><td>NCT04276688</td><td>Recruiting</td><td>China</td></tr><tr><td>Post-exposure Prophylaxis for SARS-Coronavirus-2 Drug: Hydroxychloroquine</td><td>NCT04308668</td><td>Recruiting</td><td>United States</td></tr><tr><td>A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia</td><td>NCT04276987</td><td>Not yet recruiting</td><td/></tr><tr><td>Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection</td><td>NCT04290858</td><td>Withdrawn</td><td/></tr><tr><td>Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.</td><td>NCT04290871</td><td>Withdrawn</td><td/></tr></tbody></table></table-wrap></p></sec><sec id="s0265"><label>10</label><title>Conclusion</title><p id="p0520">In conclusion, SARS-CoV-2 is a novel and highly contagious virus, and there is no specific treatment for COVID-19 disease up to now. It must be taken into account that if no effective action is taken and if drugs, vaccines, and patient tracking measures are not widely implemented or effective, intermittent social distancing is likely to continue until 2022. By that time COVID-19 might have affected 90% of the world population and kill over 40 million people <xref rid="b0925" ref-type="bibr">[185]</xref>, <xref rid="b0930" ref-type="bibr">[186]</xref>. Therefore, it is wise to continue preventive methods and public health measures until an appropriate vaccine and effective drugs are discovered. Combinational therapies with some of the above-mentioned drugs or supplements, plus an appropriate immunomodulatory diet, proper mental support and adherence to standards, will eventually be effective against COVID-19.</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="p0525">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="bi005"><title>References</title><ref id="b0005"><label>1</label><mixed-citation publication-type="other" id="h0005">Fan Y, Zhao K, Shi Z-L, Zhou P. Bat Coronaviruses in China. Viruses. 2019;11(3):210.</mixed-citation></ref><ref id="b0010"><label>2</label><element-citation publication-type="journal" id="h0010"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Horby</surname><given-names>P.W.</given-names></name><name><surname>Hayden</surname><given-names>F.G.</given-names></name><name><surname>Gao</surname><given-names>G.F.</given-names></name></person-group><article-title>A novel coronavirus outbreak of global health concern</article-title><source>The Lancet.</source><volume>395</volume><issue>10223</issue><year>2020</year><fpage>470</fpage><lpage>473</lpage></element-citation></ref><ref id="b0015"><label>3</label><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y.-R.</given-names></name><name><surname>Cao</surname><given-names>Q.-D.</given-names></name><name><surname>Hong</surname><given-names>Z.-S.</given-names></name><name><surname>Tan</surname><given-names>Y.-Y.</given-names></name><name><surname>Chen</surname><given-names>S.-D.</given-names></name><name><surname>Jin</surname><given-names>H.-J.</given-names></name></person-group><article-title>The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak&#x02013;an update on the status</article-title><source>Mil. Med. Res.</source><volume>7</volume><issue>1</issue><year>2020</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">31928528</pub-id></element-citation></ref><ref id="b0020"><label>4</label><mixed-citation publication-type="other" id="h0020">Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Eurosurveillance. 2020;25(4).</mixed-citation></ref><ref id="b0025"><label>5</label><mixed-citation publication-type="other" id="h0025">Parry J. China coronavirus: cases surge as official admits human to human transmission. British Medical Journal Publishing Group; 2020.</mixed-citation></ref><ref id="b0030"><label>6</label><element-citation publication-type="journal" id="h0030"><person-group person-group-type="author"><name><surname>Hellewell</surname><given-names>J.</given-names></name><name><surname>Abbott</surname><given-names>S.</given-names></name><name><surname>Gimma</surname><given-names>A.</given-names></name><name><surname>Bosse</surname><given-names>N.I.</given-names></name><name><surname>Jarvis</surname><given-names>C.I.</given-names></name><name><surname>Russell</surname><given-names>T.W.</given-names></name></person-group><article-title>Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts.</article-title><source>The Lancet Global Health.</source><year>2020</year></element-citation></ref><ref id="b0035"><label>7</label><element-citation publication-type="journal" id="h0035"><person-group person-group-type="author"><name><surname>Mohamed</surname><given-names>K.</given-names></name><name><surname>Rodr&#x000ed;guez-Rom&#x000e1;n</surname><given-names>E.</given-names></name><name><surname>Rahmani</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Ivanovska</surname><given-names>M.</given-names></name><name><surname>Makka</surname><given-names>S.A.</given-names></name></person-group><article-title>Borderless collaboration is needed for COVID-19; a disease that knows no borders</article-title><source>Infect Control Hosp Epidemiol</source><year>2020</year></element-citation></ref><ref id="b0040"><label>8</label><element-citation publication-type="journal" id="h0040"><person-group person-group-type="author"><name><surname>Momtazmanesh</surname><given-names>S.</given-names></name><name><surname>Ochs</surname><given-names>H.D.</given-names></name><name><surname>Uddin</surname><given-names>L.Q.</given-names></name><name><surname>Perc</surname><given-names>M.</given-names></name><name><surname>Routes</surname><given-names>J.M.</given-names></name><name><surname>Nuno Vieira</surname><given-names>D.</given-names></name></person-group><article-title>All together to Fight Novel Coronavirus Disease (COVID-19)</article-title><source>The American Journal of Tropical Medicine and Hygiene.</source><year>2020</year></element-citation></ref><ref id="b0045"><label>9</label><element-citation publication-type="journal" id="h0045"><person-group person-group-type="author"><name><surname>Hanaei</surname><given-names>S.</given-names></name><name><surname>Rezaei</surname><given-names>N.</given-names></name></person-group><article-title>COVID-19: Developing from an outbreak to a pandemic</article-title><source>Arch Med Res</source><year>2020</year></element-citation></ref><ref id="b0050"><label>10</label><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>X.-L.</given-names></name><name><surname>Wang</surname><given-names>X.-G.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name></person-group><article-title>Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin</article-title><source>BioRxiv.</source><year>2020</year></element-citation></ref><ref id="b0055"><label>11</label><element-citation publication-type="journal" id="h0055"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>Y.-M.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Song</surname><given-names>Z.-G.</given-names></name></person-group><article-title>A new coronavirus associated with human respiratory disease in China</article-title><source>Nature</source><volume>579</volume><issue>7798</issue><year>2020</year><fpage>265</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">32015508</pub-id></element-citation></ref><ref id="b0060"><label>12</label><mixed-citation publication-type="other" id="h0060">Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. Published online February 3, 2020. 2020.</mixed-citation></ref><ref id="b0065"><label>13</label><element-citation publication-type="journal" id="h0065"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>T.T.-Y.</given-names></name><name><surname>Shum</surname><given-names>M.H.-H.</given-names></name><name><surname>Zhu</surname><given-names>H.-C.</given-names></name><name><surname>Tong</surname><given-names>Y.-G.</given-names></name><name><surname>Ni</surname><given-names>X.-B.</given-names></name><name><surname>Liao</surname><given-names>Y.-S.</given-names></name></person-group><article-title>Identification of 2019-nCoV related coronaviruses in Malayan pangolins in southern China</article-title><source>BioRxiv.</source><year>2020</year></element-citation></ref><ref id="b0070"><label>14</label><element-citation publication-type="journal" id="h0070"><person-group person-group-type="author"><name><surname>Paraskevis</surname><given-names>D.</given-names></name><name><surname>Kostaki</surname><given-names>E.G.</given-names></name><name><surname>Magiorkinis</surname><given-names>G.</given-names></name><name><surname>Panayiotakopoulos</surname><given-names>G.</given-names></name><name><surname>Sourvinos</surname><given-names>G.</given-names></name><name><surname>Tsiodras</surname><given-names>S.</given-names></name></person-group><article-title>Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event</article-title><source>Infection, Genetics and Evolution.</source><volume>79</volume><year>2020</year></element-citation></ref><ref id="b0075"><label>15</label><mixed-citation publication-type="other" id="h0075">Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health&#x02014;The latest 2019 novel coronavirus outbreak in Wuhan, China. International Journal of Infectious Diseases. 2020;91:264-6.</mixed-citation></ref><ref id="b0080"><label>16</label><element-citation publication-type="journal" id="h0080"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>N.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Qu</surname><given-names>J.</given-names></name><name><surname>Gong</surname><given-names>F.</given-names></name><name><surname>Han</surname><given-names>Y.</given-names></name></person-group><article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</article-title><source>The Lancet.</source><volume>395</volume><issue>10223</issue><year>2020</year><fpage>507</fpage><lpage>513</lpage></element-citation></ref><ref id="b0085"><label>17</label><element-citation publication-type="journal" id="h0085"><person-group person-group-type="author"><name><surname>Cascella</surname><given-names>M.</given-names></name><name><surname>Rajnik</surname><given-names>M.</given-names></name><name><surname>Cuomo</surname><given-names>A.</given-names></name><name><surname>Dulebohn</surname><given-names>S.C.</given-names></name><name><surname>Di Napoli</surname><given-names>R.</given-names></name></person-group><article-title>Features, evaluation and treatment coronavirus (COVID-19). Statpearls [internet]</article-title><source>StatPearls Publishing</source><year>2020</year></element-citation></ref><ref id="b0090"><label>18</label><mixed-citation publication-type="other" id="h0090">(WHO) WHO. Q&#x00026;A on coronaviruses (COVID-19) 2020 17 April [Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/q-a-coronaviruses#:~:text=symptoms.</mixed-citation></ref><ref id="b0095"><label>19</label><element-citation publication-type="journal" id="h0095"><person-group person-group-type="author"><name><surname>Sahin</surname><given-names>A.R.</given-names></name><name><surname>Erdogan</surname><given-names>A.</given-names></name><name><surname>Agaoglu</surname><given-names>P.M.</given-names></name><name><surname>Dineri</surname><given-names>Y.</given-names></name><name><surname>Cakirci</surname><given-names>A.Y.</given-names></name><name><surname>Senel</surname><given-names>M.E.</given-names></name></person-group><article-title>2019 Novel Coronavirus (COVID-19) Outbreak: A Review of the Current Literature</article-title><source>EJMO.</source><volume>4</volume><issue>1</issue><year>2020</year><fpage>1</fpage><lpage>7</lpage></element-citation></ref><ref id="b0100"><label>20</label><element-citation publication-type="journal" id="h0100"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>W.K.</given-names></name><name><surname>To</surname><given-names>K.-f</given-names></name><name><surname>Chan</surname><given-names>P.K.</given-names></name><name><surname>Chan</surname><given-names>H.L.</given-names></name><name><surname>Wu</surname><given-names>A.K.</given-names></name><name><surname>Lee</surname><given-names>N.</given-names></name></person-group><article-title>Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection</article-title><source>Gastroenterology</source><volume>125</volume><issue>4</issue><year>2003</year><fpage>1011</fpage><lpage>1017</lpage><pub-id pub-id-type="pmid">14517783</pub-id></element-citation></ref><ref id="b0105"><label>21</label><element-citation publication-type="journal" id="h0105"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Cheng</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Tian</surname><given-names>C.</given-names></name></person-group><article-title>Clinical Features of COVID-19-Related Liver Damage</article-title><source>Clinical Gastroenterology and Hepatology</source><year>2020</year></element-citation></ref><ref id="b0110"><label>22</label><element-citation publication-type="journal" id="h0110"><person-group person-group-type="author"><name><surname>Rezaei</surname><given-names>N.</given-names></name></person-group><article-title>COVID-19 affects healthy pediatricians more than pediatric patients</article-title><source>Infection Control &#x00026; Hospital Epidemiology</source><year>2020</year></element-citation></ref><ref id="b0115"><label>23</label><element-citation publication-type="journal" id="h0115"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>Y.</given-names></name><name><surname>Mo</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Qi</surname><given-names>X.</given-names></name><name><surname>Jiang</surname><given-names>F.</given-names></name><name><surname>Jiang</surname><given-names>Z.</given-names></name></person-group><article-title>Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China</article-title><source>Pediatrics</source><year>2020</year></element-citation></ref><ref id="b0120"><label>24</label><mixed-citation publication-type="other" id="h0120">Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, et al. Epidemiology and Transmission of COVID-19 in Shenzhen China: Analysis of 391 cases and 1,286 of their close contacts. medRxiv. 2020.</mixed-citation></ref><ref id="b0125"><label>25</label><element-citation publication-type="journal" id="h0125"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Du</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Y.Y.</given-names></name><name><surname>Qu</surname><given-names>J.</given-names></name></person-group><article-title>SARS-CoV-2 Infection in Children</article-title><source>N. Engl. J. Med.</source><year>2020</year></element-citation></ref><ref id="b0130"><label>26</label><element-citation publication-type="journal" id="h0130"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>V.G.</given-names></name><name><surname>Mills</surname><given-names>M.</given-names></name><name><surname>Suarez</surname><given-names>D.</given-names></name><name><surname>Hogan</surname><given-names>C.A.</given-names></name><name><surname>Yeh</surname><given-names>D.</given-names></name><name><surname>Segal</surname><given-names>J.B.</given-names></name></person-group><article-title>COVID-19 and Kawasaki disease: novel virus and novel case. Hospital</article-title><source>Pediatrics</source><volume>hpeds</volume><year>2020</year><fpage>2020</fpage><lpage>10123</lpage></element-citation></ref><ref id="b0135"><label>27</label><mixed-citation publication-type="other" id="h0135">Liu Y, Ning Z, Chen Y, Guo M, Liu Y, Gali NK, et al. Aerodynamic characteristics and RNA concentration of SARS-CoV-2 aerosol in Wuhan hospitals during COVID-19 outbreak. bioRxiv. 2020.</mixed-citation></ref><ref id="b0140"><label>28</label><element-citation publication-type="journal" id="h0140"><person-group person-group-type="author"><name><surname>van Doremalen</surname><given-names>N.</given-names></name><name><surname>Bushmaker</surname><given-names>T.</given-names></name><name><surname>Morris</surname><given-names>D.H.</given-names></name><name><surname>Holbrook</surname><given-names>M.G.</given-names></name><name><surname>Gamble</surname><given-names>A.</given-names></name><name><surname>Williamson</surname><given-names>B.N.</given-names></name></person-group><article-title>Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1</article-title><source>N. Engl. J. Med.</source><year>2020</year></element-citation></ref><ref id="b0145"><label>29</label><mixed-citation publication-type="other" id="h0145">Santarpia JL, Rivera DN, Herrera V, Morwitzer MJ, Creager H, Santarpia GW, et al. Transmission Potential of SARS-CoV-2 in Viral Shedding Observed at the University of Nebraska Medical Center. medRxiv. 2020.</mixed-citation></ref><ref id="b0150"><label>30</label><mixed-citation publication-type="other" id="h0150">McIntosh K, Hirsch MS, Bloom A. Coronavirus disease 2019 (COVID-19). UpToDate Hirsch MS, Bloom A (Eds) Accessed Mar. 2020;5.</mixed-citation></ref><ref id="b0155"><label>31</label><element-citation publication-type="journal" id="h0155"><person-group person-group-type="author"><name><surname>Rothe</surname><given-names>C.</given-names></name><name><surname>Schunk</surname><given-names>M.</given-names></name><name><surname>Sothmann</surname><given-names>P.</given-names></name><name><surname>Bretzel</surname><given-names>G.</given-names></name><name><surname>Froeschl</surname><given-names>G.</given-names></name><name><surname>Wallrauch</surname><given-names>C.</given-names></name></person-group><article-title>Transmission of 2019-nCoV infection from an asymptomatic contact in Germany</article-title><source>N. Engl. J. Med.</source><year>2020</year></element-citation></ref><ref id="b0160"><label>32</label><element-citation publication-type="journal" id="h0160"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>P.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Han</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name></person-group><article-title>A familial cluster of infection associated with the 2019 novel coronavirus indicating potential person-to-person transmission during the incubation period</article-title><source>J Infect Dis.</source><year>2020</year></element-citation></ref><ref id="b0165"><label>33</label><element-citation publication-type="journal" id="h0165"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>Y.</given-names></name><name><surname>Yao</surname><given-names>L.</given-names></name><name><surname>Wei</surname><given-names>T.</given-names></name><name><surname>Tian</surname><given-names>F.</given-names></name><name><surname>Jin</surname><given-names>D.-Y.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name></person-group><article-title>Presumed asymptomatic carrier transmission of COVID-19</article-title><source>JAMA</source><year>2020</year></element-citation></ref><ref id="b0170"><label>34</label><mixed-citation publication-type="other" id="h0170">Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. Radiology. 2020:200370.</mixed-citation></ref><ref id="b0175"><label>35</label><element-citation publication-type="journal" id="h0175"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Du</surname><given-names>R.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name></person-group><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title><source>The Lancet</source><year>2020</year></element-citation></ref><ref id="b0180"><label>36</label><element-citation publication-type="journal" id="h0180"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>C.</given-names></name><name><surname>Tang</surname><given-names>L.</given-names></name><name><surname>Hong</surname><given-names>Z.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name></person-group><article-title>Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. The Lancet</article-title><source>Gastroenterology &#x00026; Hepatology.</source><year>2020</year></element-citation></ref><ref id="b0185"><label>37</label><element-citation publication-type="journal" id="h0185"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>L.</given-names></name><name><surname>Xu</surname><given-names>D.</given-names></name><name><surname>Ye</surname><given-names>G.</given-names></name><name><surname>Xia</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Positive RT-PCR test results in patients recovered from COVID-19</article-title><source>JAMA</source><year>2020</year></element-citation></ref><ref id="b0190"><label>38</label><mixed-citation publication-type="other" id="h0190">Tang A, Tong Z, Wang H, Dai Y, Li K, Liu J, et al. Detection of Novel Coronavirus by RT-PCR in Stool Specimen from Asymptomatic Child, China. Emerging infectious diseases. 2020;26(6).</mixed-citation></ref><ref id="b0195"><label>39</label><element-citation publication-type="journal" id="h0195"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>R.</given-names></name><name><surname>Lu</surname><given-names>R.</given-names></name><name><surname>Han</surname><given-names>K.</given-names></name><name><surname>Wu</surname><given-names>G.</given-names></name></person-group><article-title>Detection of SARS-CoV-2 in Different Types of</article-title><source>Clinical Specimens. Jama.</source><year>2020</year></element-citation></ref><ref id="b0200"><label>40</label><mixed-citation publication-type="other" id="h0200">Song C, Wang Y, Li W, Hu B, Chen G, Xia P, et al. Detection of 2019 novel coronavirus in semen and testicular biopsy specimen of COVID-19 patients. medRxiv. 2020:2020.03.31.20042333.</mixed-citation></ref><ref id="b0205"><label>41</label><mixed-citation publication-type="other" id="h0205">Li Y, Zhao R, Zheng S, Chen X, Wang J, Sheng X, et al. Lack of Vertical Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, China. Emerging infectious diseases. 2020;26(6).</mixed-citation></ref><ref id="b0210"><label>42</label><mixed-citation publication-type="other" id="h0210">Network J. Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn 2020 March 26 [Available from: https://jamanetwork.com/journals/jama/fullarticle/2763853.</mixed-citation></ref><ref id="b0215"><label>43</label><mixed-citation publication-type="other" id="h0215">Network J. Antibodies in Infants Born to Mothers With COVID-19 Pneumonia 2020 March 26 [Available from: https://jamanetwork.com/journals/jama/fullarticle/2763854.</mixed-citation></ref><ref id="b0220"><label>44</label><element-citation publication-type="journal" id="h0220"><person-group person-group-type="author"><name><surname>Peeri</surname><given-names>N.C.</given-names></name><name><surname>Shrestha</surname><given-names>N.</given-names></name><name><surname>Rahman</surname><given-names>M.S.</given-names></name><name><surname>Zaki</surname><given-names>R.</given-names></name><name><surname>Tan</surname><given-names>Z.</given-names></name><name><surname>Bibi</surname><given-names>S.</given-names></name></person-group><article-title>The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?</article-title><source>Int. J. Epidemiol.</source><year>2020</year></element-citation></ref><ref id="b0225"><label>45</label><element-citation publication-type="journal" id="h0225"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>J.</given-names></name><name><surname>Wen</surname><given-names>Z.</given-names></name><name><surname>Zhong</surname><given-names>G.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name></person-group><article-title>Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS&#x02013;coronavirus 2</article-title><source>Science</source><year>2020</year></element-citation></ref><ref id="b0230"><label>46</label><mixed-citation publication-type="other" id="h0230">STRAITSTIMES T. Second dog in Hong Kong tests positive for coronavirus 2020 MAR 20 [Available from: https://www.straitstimes.com/asia/east-asia/second-dog-in-hong-kong-tests-positive-for-coronavirus.</mixed-citation></ref><ref id="b0235"><label>47</label><mixed-citation publication-type="other" id="h0235">Wilder-Smith A, Freedman D. Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak. Journal of travel medicine. 2020;27(2):taaa020.</mixed-citation></ref><ref id="b0240"><label>48</label><mixed-citation publication-type="other" id="h0240">Pirouz B, Golmohammadi A, Masouleh HS, Violini G, Pirouz B. Relationship between Average Daily Temperature and Average Cumulative Daily Rate of Confirmed Cases of COVID-19. medRxiv. 2020.</mixed-citation></ref><ref id="b0245"><label>49</label><mixed-citation publication-type="other" id="h0245">Sajadi MM, Habibzadeh P, Vintzileos A, Shokouhi S, Miralles-Wilhelm F, Amoroso A. Temperature and latitude analysis to predict potential spread and seasonality for COVID-19. Available at SSRN 3550308. 2020.</mixed-citation></ref><ref id="b0250"><label>50</label><mixed-citation publication-type="other" id="h0250">Control ECfDPa. Situation update worldwide, as of 28 March 2020 2020 March 28 [Available from: https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases.</mixed-citation></ref><ref id="b0255"><label>51</label><mixed-citation publication-type="other" id="h0255">World Mo. World Climate Map 2020 February 27 [Available from: https://www.mapsofworld.com/world-maps/world-climate-map.html.</mixed-citation></ref><ref id="b0260"><label>52</label><mixed-citation publication-type="other" id="h0260">Organization WH. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020 2020March 11 [Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.</mixed-citation></ref><ref id="b0265"><label>53</label><mixed-citation publication-type="other" id="h0265">uvex. Respiratory protection 2020 March 30 [Available from: https://www.uvex.co.za/en/products/respiratory-protection/.</mixed-citation></ref><ref id="b0270"><label>54</label><mixed-citation publication-type="other" id="h0270">ecdc. Cloth masks and mask sterilisation as options in case of shortage of surgical masks and respirators 2020 March 26 [Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Cloth-face-masks-in-case-shortage-surgical-masks-respirators2020-03-26.pdf.</mixed-citation></ref><ref id="b0275"><label>55</label><mixed-citation publication-type="other" id="h0275">Desai AN, Patel P. Stopping the Spread of COVID-19. JAMA.</mixed-citation></ref><ref id="b0280"><label>56</label><mixed-citation publication-type="other" id="h0280">Wang X, Pan Z, Cheng Z. Association between 2019-nCoV transmission and N95 respirator use. medRxiv. 2020.</mixed-citation></ref><ref id="b0285"><label>57</label><mixed-citation publication-type="other" id="h0285">Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance. 2020;25(3).</mixed-citation></ref><ref id="b0290"><label>58</label><element-citation publication-type="journal" id="h0290"><person-group person-group-type="author"><name><surname>Morrow</surname><given-names>E.S.</given-names></name><name><surname>Roseweir</surname><given-names>A.</given-names></name><name><surname>Edwards</surname><given-names>J.</given-names></name></person-group><article-title>The role of gamma delta T lymphocytes in breast cancer: a review</article-title><source>Translational Research.</source><volume>203</volume><year>2019</year><fpage>88</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">30194922</pub-id></element-citation></ref><ref id="b0295"><label>59</label><element-citation publication-type="journal" id="h0295"><person-group person-group-type="author"><name><surname>Saghazadeh</surname><given-names>A.</given-names></name><name><surname>Rezaei</surname><given-names>N.</given-names></name></person-group><article-title>Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids</article-title><source>Int. Immunopharmacol.</source><volume>84</volume><issue>106560</issue><year>2020</year><fpage>1</fpage><lpage>6</lpage></element-citation></ref><ref id="b0300"><label>60</label><mixed-citation publication-type="other" id="h0300">HolshueML D, LindquistS L, WiesmanJ B, SpittersC E, WilkersonS T. FirstCaseof2019NovelCoronavirusintheUnitedStates. NEnglJ Med2020 101056/NEJMoa2001191. 2020.</mixed-citation></ref><ref id="b0305"><label>61</label><mixed-citation publication-type="other" id="h0305">(NIH) NIoH. COVID-19 Treatment Guidelines 2020 April 21 [Available from: https://covid19treatmentguidelines.nih.gov/introduction/.</mixed-citation></ref><ref id="b0310"><label>62</label><element-citation publication-type="journal" id="h0310"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>P.</given-names></name><name><surname>Griffin</surname><given-names>I.</given-names></name><name><surname>Tucker</surname><given-names>C.</given-names></name><name><surname>Smith</surname><given-names>D.</given-names></name><name><surname>Oechsle</surname><given-names>O.</given-names></name><name><surname>Phelan</surname><given-names>A.</given-names></name></person-group><article-title>Baricitinib as potential treatment for 2019-nCoV acute respiratory disease</article-title><source>The lancet.</source><volume>395</volume><issue>10223</issue><year>2020</year><fpage>e30</fpage><lpage>e31</lpage></element-citation></ref><ref id="b0315"><label>63</label><element-citation publication-type="book" id="h0315"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Hu</surname><given-names>C.</given-names></name><name><surname>Zhu</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name></person-group><chapter-title>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus&#x02013;infected pneumonia in Wuhan</chapter-title><year>2020</year><publisher-name>China</publisher-name><publisher-loc>Jama</publisher-loc></element-citation></ref><ref id="b0320"><label>64</label><mixed-citation publication-type="other" id="h0320">Li H, Wang Y, Xu J, Cao B. Potential antiviral therapeutics for 2019 Novel Coronavirus. Zhonghua jie he he hu xi za zhi= Zhonghua jiehe he huxi zazhi= Chinese journal of tuberculosis and respiratory diseases. 2020;43:E002-E.</mixed-citation></ref><ref id="b0325"><label>65</label><element-citation publication-type="book" id="h0325"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Cai</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>H.</given-names></name></person-group><chapter-title>Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan</chapter-title><year>2020</year><publisher-name>China</publisher-name><publisher-loc>JAMA internal medicine</publisher-loc></element-citation></ref><ref id="b0330"><label>66</label><mixed-citation publication-type="other" id="h0330">Li H, Wang Y, Xu J, Cao B. Potential antiviral therapeutics for 2019 Novel Coronavirus. Zhonghua jie he he hu xi za zhi= Zhonghua jiehe he huxi zazhi= Chinese journal of tuberculosis and respiratory diseases. 2020;43:E002.</mixed-citation></ref><ref id="b0335"><label>67</label><mixed-citation publication-type="other" id="h0335">De Clercq E. New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections. Chemistry&#x02013;An Asian Journal. 2019;14(22):3962-8.</mixed-citation></ref><ref id="b0340"><label>68</label><element-citation publication-type="journal" id="h0340"><person-group person-group-type="author"><name><surname>Oestereich</surname><given-names>L.</given-names></name><name><surname>L&#x000fc;dtke</surname><given-names>A.</given-names></name><name><surname>Wurr</surname><given-names>S.</given-names></name><name><surname>Rieger</surname><given-names>T.</given-names></name><name><surname>Mu&#x000f1;oz-Fontela</surname><given-names>C.</given-names></name><name><surname>G&#x000fc;nther</surname><given-names>S.</given-names></name></person-group><article-title>Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model</article-title><source>Antiviral Res.</source><volume>105</volume><year>2014</year><fpage>17</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">24583123</pub-id></element-citation></ref><ref id="b0345"><label>69</label><element-citation publication-type="journal" id="h0345"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Cao</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name></person-group><article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</article-title><source>Cell Res.</source><volume>30</volume><issue>3</issue><year>2020</year><fpage>269</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">32020029</pub-id></element-citation></ref><ref id="b0350"><label>70</label><mixed-citation publication-type="other" id="h0350">ARENA CT. Favilavir approved as experimental coronavirus drug. 2020 FEBRUARY 21.</mixed-citation></ref><ref id="b0355"><label>71</label><element-citation publication-type="journal" id="h0355"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A.</given-names></name><name><surname>Chan</surname><given-names>J.F.</given-names></name><name><surname>Azhar</surname><given-names>E.I.</given-names></name><name><surname>Hui</surname><given-names>D.S.</given-names></name><name><surname>Yuen</surname><given-names>K.-Y.</given-names></name></person-group><article-title>Coronaviruses&#x02014;drug discovery and therapeutic options</article-title><source>Nat. Rev. Drug Discovery</source><volume>15</volume><issue>5</issue><year>2016</year><fpage>327</fpage><pub-id pub-id-type="pmid">26868298</pub-id></element-citation></ref><ref id="b0360"><label>72</label><element-citation publication-type="journal" id="h0360"><person-group person-group-type="author"><name><surname>Falzarano</surname><given-names>D.</given-names></name><name><surname>De Wit</surname><given-names>E.</given-names></name><name><surname>Rasmussen</surname><given-names>A.L.</given-names></name><name><surname>Feldmann</surname><given-names>F.</given-names></name><name><surname>Okumura</surname><given-names>A.</given-names></name><name><surname>Scott</surname><given-names>D.P.</given-names></name></person-group><article-title>Treatment with interferon-&#x003b1;2b and ribavirin improves outcome in MERS-CoV&#x02013;infected rhesus macaques</article-title><source>Nat. Med.</source><volume>19</volume><issue>10</issue><year>2013</year><fpage>1313</fpage><lpage>1317</lpage><pub-id pub-id-type="pmid">24013700</pub-id></element-citation></ref><ref id="b0365"><label>73</label><element-citation publication-type="journal" id="h0365"><person-group person-group-type="author"><name><surname>Arabi</surname><given-names>Y.M.</given-names></name><name><surname>Shalhoub</surname><given-names>S.</given-names></name><name><surname>Mandourah</surname><given-names>Y.</given-names></name><name><surname>Al-Hameed</surname><given-names>F.</given-names></name><name><surname>Al-Omari</surname><given-names>A.</given-names></name><name><surname>Al Qasim</surname><given-names>E.</given-names></name></person-group><article-title>Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study</article-title><source>Clin. Infect. Dis.</source><year>2019</year></element-citation></ref><ref id="b0370"><label>74</label><element-citation publication-type="journal" id="h0370"><person-group person-group-type="author"><name><surname>Elfiky</surname><given-names>A.A.</given-names></name></person-group><article-title>Anti-HCV, nucleotide inhibitors, repurposing against COVID-19</article-title><source>Life Sci.</source><volume>117477</volume><year>2020</year></element-citation></ref><ref id="b0375"><label>75</label><mixed-citation publication-type="other" id="h0375">Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Science translational medicine. 2017;9(396).</mixed-citation></ref><ref id="b0380"><label>76</label><element-citation publication-type="journal" id="h0380"><person-group person-group-type="author"><name><surname>Holshue</surname><given-names>M.L.</given-names></name><name><surname>DeBolt</surname><given-names>C.</given-names></name><name><surname>Lindquist</surname><given-names>S.</given-names></name><name><surname>Lofy</surname><given-names>K.H.</given-names></name><name><surname>Wiesman</surname><given-names>J.</given-names></name><name><surname>Bruce</surname><given-names>H.</given-names></name></person-group><source>N. Engl. J. Med.</source><year>2020</year></element-citation></ref><ref id="b0385"><label>77</label><element-citation publication-type="journal" id="h0385"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Cao</surname><given-names>R.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Hu</surname><given-names>H.</given-names></name></person-group><article-title>Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro</article-title><source>Cell Discovery</source><volume>6</volume><issue>1</issue><year>2020</year><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">31934347</pub-id></element-citation></ref><ref id="b0390"><label>78</label><mixed-citation publication-type="other" id="h0390">(FDA) FaDA. Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment 2020 May 01 [Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment.</mixed-citation></ref><ref id="b0395"><label>79</label><element-citation publication-type="journal" id="h0395"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Guo</surname><given-names>D.</given-names></name></person-group><article-title>Emerging coronaviruses: genome structure, replication, and pathogenesis</article-title><source>J. Med. Virol.</source><year>2020</year></element-citation></ref><ref id="b0400"><label>80</label><element-citation publication-type="book" id="h0400"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>De Clercq</surname><given-names>E.</given-names></name></person-group><chapter-title>Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature</chapter-title><year>2020</year><publisher-name>Publishing Group</publisher-name></element-citation></ref><ref id="b0405"><label>81</label><element-citation publication-type="journal" id="h0405"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>J.</given-names></name><name><surname>Jeon</surname><given-names>S.</given-names></name><name><surname>Shin</surname><given-names>H.-Y.</given-names></name><name><surname>Kim</surname><given-names>M.J.</given-names></name><name><surname>Seong</surname><given-names>Y.M.</given-names></name><name><surname>Lee</surname><given-names>W.J.</given-names></name></person-group><article-title>Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR</article-title><source>J. Korean Med. Sci.</source><year>2020;35(6).</year></element-citation></ref><ref id="b0410"><label>82</label><element-citation publication-type="journal" id="h0410"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wen</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name></person-group><article-title>A trial of lopinavir&#x02013;ritonavir in adults hospitalized with severe Covid-19</article-title><source>N. Engl. J. Med.</source><year>2020</year></element-citation></ref><ref id="b0415"><label>83</label><element-citation publication-type="journal" id="h0415"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>M.-H.</given-names></name><name><surname>Moses</surname><given-names>D.C.</given-names></name><name><surname>Hsieh</surname><given-names>C.-H.</given-names></name><name><surname>Cheng</surname><given-names>S.-C.</given-names></name><name><surname>Chen</surname><given-names>Y.-H.</given-names></name><name><surname>Sun</surname><given-names>C.-Y.</given-names></name></person-group><article-title>Disulfiram can inhibit mers and sars coronavirus papain-like proteases via different modes</article-title><source>Antiviral Res.</source><volume>150</volume><year>2018</year><fpage>155</fpage><lpage>163</lpage><pub-id pub-id-type="pmid">29289665</pub-id></element-citation></ref><ref id="b0420"><label>84</label><element-citation publication-type="journal" id="h0420"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Gui</surname><given-names>C.</given-names></name><name><surname>Luo</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>Q.</given-names></name><name><surname>G&#x000fc;nther</surname><given-names>S.</given-names></name><name><surname>Scandella</surname><given-names>E.</given-names></name></person-group><article-title>Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro</article-title><source>J. Virol.</source><volume>79</volume><issue>11</issue><year>2005</year><fpage>7095</fpage><lpage>7103</lpage><pub-id pub-id-type="pmid">15890949</pub-id></element-citation></ref><ref id="b0425"><label>85</label><mixed-citation publication-type="other" id="h0425">Jo S, Kim S, Shin DH, Kim M-S. Inhibition of SARS-CoV 3CL protease by flavonoids. Journal of enzyme inhibition and medicinal chemistry. 2020;35(1):145-51.</mixed-citation></ref><ref id="b0430"><label>86</label><mixed-citation publication-type="other" id="h0430">Rismanbaf A. Potential treatments for COVID-19; a literature review. Archives of Academic Emergency Medicine.8(1):29.</mixed-citation></ref><ref id="b0435"><label>87</label><element-citation publication-type="book" id="h0435"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>B.R.</given-names></name><name><surname>Shin</surname><given-names>B.</given-names></name><name><surname>Choi</surname><given-names>Y.</given-names></name><name><surname>Park</surname><given-names>S.</given-names></name><name><surname>Kang</surname><given-names>K.</given-names></name></person-group><chapter-title>Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV)</chapter-title><year>2020</year><publisher-name>China through a drug-target interaction deep learning model. bioRxiv</publisher-name><publisher-loc>Wuhan</publisher-loc></element-citation></ref><ref id="b0440"><label>88</label><mixed-citation publication-type="other" id="h0440">Wang Q, Zhao Y, Chen X, Hong A. Virtual Screening of Approved Clinic Drugs with Main Protease (3CLpro) Reveals Potential Inhibitory Effects on SARS-CoV-2. 2020.</mixed-citation></ref><ref id="b0445"><label>89</label><element-citation publication-type="journal" id="h0445"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.W.</given-names></name><name><surname>Yiu</surname><given-names>C.-P.</given-names></name><name><surname>Wong</surname><given-names>K.-Y.</given-names></name></person-group><article-title>Prediction of the 2019-nCoV 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates</article-title><source>ChemRxiv</source><year>2020</year></element-citation></ref><ref id="b0450"><label>90</label><element-citation publication-type="journal" id="h0450"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J.-Y.</given-names></name><name><surname>Jeong</surname><given-names>H.J.</given-names></name><name><surname>Kim</surname><given-names>J.H.</given-names></name><name><surname>Kim</surname><given-names>Y.M.</given-names></name><name><surname>Park</surname><given-names>S.-J.</given-names></name><name><surname>Kim</surname><given-names>D.</given-names></name></person-group><article-title>Diarylheptanoids from Alnus japonica inhibit papain-like protease of severe acute respiratory syndrome coronavirus</article-title><source>Biol. Pharm. Bull.</source><year>2012</year><fpage>b12</fpage><lpage>00623</lpage></element-citation></ref><ref id="b0455"><label>91</label><mixed-citation publication-type="other" id="h0455">Elfiky AA, Ibrahim NS. Anti-SARS and Anti-HCV Drugs Repurposing Against the Papain-like Protease of the Newly Emerged Coronavirus (2019-nCoV). 2020.</mixed-citation></ref><ref id="b0460"><label>92</label><element-citation publication-type="journal" id="h0460"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>L.</given-names></name><name><surname>Hu</surname><given-names>S.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name></person-group><article-title>Discovering drugs to treat coronavirus disease 2019 (COVID-19)</article-title><source>Drug Discoveries &#x00026; Therapeutics.</source><volume>14</volume><issue>1</issue><year>2020</year><fpage>58</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">32147628</pub-id></element-citation></ref><ref id="b0465"><label>93</label><element-citation publication-type="journal" id="h0465"><person-group person-group-type="author"><name><surname>Arya</surname><given-names>R.</given-names></name><name><surname>Das</surname><given-names>A.</given-names></name><name><surname>Prashar</surname><given-names>V.</given-names></name><name><surname>Kumar</surname><given-names>M.</given-names></name></person-group><article-title>Potential inhibitors against papain-like protease of novel coronavirus (SARS-CoV-2) from</article-title><source>FDA approved drugs.</source><year>2020</year></element-citation></ref><ref id="b0470"><label>94</label><mixed-citation publication-type="other" id="h0470">Chen H, Zhang Z, Wang L, Huang Z, Gong F, Li X, et al. First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients. medRxiv. 2020.</mixed-citation></ref><ref id="b0475"><label>95</label><element-citation publication-type="journal" id="h0475"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M.</given-names></name><name><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name><surname>Schroeder</surname><given-names>S.</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>N.</given-names></name><name><surname>Herrler</surname><given-names>T.</given-names></name><name><surname>Erichsen</surname><given-names>S.</given-names></name></person-group><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title><source>Cell</source><year>2020</year></element-citation></ref><ref id="b0480"><label>96</label><element-citation publication-type="journal" id="h0480"><person-group person-group-type="author"><name><surname>Meuleman</surname><given-names>P.</given-names></name><name><surname>Albecka</surname><given-names>A.</given-names></name><name><surname>Belouzard</surname><given-names>S.</given-names></name><name><surname>Vercauteren</surname><given-names>K.</given-names></name><name><surname>Verhoye</surname><given-names>L.</given-names></name><name><surname>Wychowski</surname><given-names>C.</given-names></name></person-group><article-title>Griffithsin has antiviral activity against hepatitis C virus</article-title><source>Antimicrob. Agents Chemother.</source><volume>55</volume><issue>11</issue><year>2011</year><fpage>5159</fpage><lpage>5167</lpage><pub-id pub-id-type="pmid">21896910</pub-id></element-citation></ref><ref id="b0485"><label>97</label><element-citation publication-type="journal" id="h0485"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>T.</given-names></name><name><surname>O'Keefe</surname><given-names>B.R.</given-names></name><name><surname>Sowder</surname><given-names>R.C.</given-names></name><name><surname>Bringans</surname><given-names>S.</given-names></name><name><surname>Gardella</surname><given-names>R.</given-names></name><name><surname>Berg</surname><given-names>S.</given-names></name></person-group><article-title>Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp</article-title><source>J. Biol. Chem.</source><volume>280</volume><issue>10</issue><year>2005</year><fpage>9345</fpage><lpage>9353</lpage><pub-id pub-id-type="pmid">15613479</pub-id></element-citation></ref><ref id="b0490"><label>98</label><element-citation publication-type="journal" id="h0490"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>C.</given-names></name></person-group><article-title>Griffithsin, a Highly Potent Broad-Spectrum Antiviral Lectin from Red Algae: From Discovery to Clinical Application</article-title><source>Mar. Drugs</source><volume>17</volume><issue>10</issue><year>2019</year><fpage>567</fpage></element-citation></ref><ref id="b0495"><label>99</label><element-citation publication-type="journal" id="h0495"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Luo</surname><given-names>R.</given-names></name><name><surname>Zeng</surname><given-names>L.</given-names></name><name><surname>Telegina</surname><given-names>I.</given-names></name><name><surname>Vlassov</surname><given-names>V.V.</given-names></name></person-group><article-title>Arbidol for preventing and treating influenza in adults and children. The Cochrane database of systematic</article-title><source>reviews.</source><year>2017;2017(2).</year></element-citation></ref><ref id="b0500"><label>100</label><element-citation publication-type="journal" id="h0500"><person-group person-group-type="author"><name><surname>Aguiar</surname><given-names>A.C.</given-names></name><name><surname>Murce</surname><given-names>E.</given-names></name><name><surname>Cortopassi</surname><given-names>W.A.</given-names></name><name><surname>Pimentel</surname><given-names>A.S.</given-names></name><name><surname>Almeida</surname><given-names>M.M.</given-names></name><name><surname>Barros</surname><given-names>D.C.</given-names></name></person-group><article-title>Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity</article-title><source>International Journal for Parasitology: Drugs and Drug Resistance.</source><volume>8</volume><issue>3</issue><year>2018</year><fpage>459</fpage><lpage>464</lpage><pub-id pub-id-type="pmid">30396013</pub-id></element-citation></ref><ref id="b0505"><label>101</label><element-citation publication-type="journal" id="h0505"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>M.J.</given-names></name><name><surname>Bergeron</surname><given-names>E.</given-names></name><name><surname>Benjannet</surname><given-names>S.</given-names></name><name><surname>Erickson</surname><given-names>B.R.</given-names></name><name><surname>Rollin</surname><given-names>P.E.</given-names></name><name><surname>Ksiazek</surname><given-names>T.G.</given-names></name></person-group><article-title>Chloroquine is a potent inhibitor of SARS coronavirus infection and spread</article-title><source>Virology journal.</source><volume>2</volume><issue>1</issue><year>2005</year><fpage>69</fpage><pub-id pub-id-type="pmid">16115318</pub-id></element-citation></ref><ref id="b0510"><label>102</label><element-citation publication-type="journal" id="h0510"><person-group person-group-type="author"><name><surname>Golden</surname><given-names>E.B.</given-names></name><name><surname>Cho</surname><given-names>H.-Y.</given-names></name><name><surname>Hofman</surname><given-names>F.M.</given-names></name><name><surname>Louie</surname><given-names>S.G.</given-names></name><name><surname>Sch&#x000f6;nthal</surname><given-names>A.H.</given-names></name><name><surname>Chen</surname><given-names>T.C.</given-names></name></person-group><article-title>Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors</article-title><source>Neurosurg. Focus</source><volume>38</volume><issue>3</issue><year>2015</year><fpage>E12</fpage></element-citation></ref><ref id="b0515"><label>103</label><element-citation publication-type="journal" id="h0515"><person-group person-group-type="author"><name><surname>Savarino</surname><given-names>A.</given-names></name><name><surname>Di Trani</surname><given-names>L.</given-names></name><name><surname>Donatelli</surname><given-names>I.</given-names></name><name><surname>Cauda</surname><given-names>R.</given-names></name><name><surname>Cassone</surname><given-names>A.</given-names></name></person-group><article-title>New insights into the antiviral effects of chloroquine</article-title><source>Lancet. Infect. Dis</source><volume>6</volume><issue>2</issue><year>2006</year><fpage>67</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">16439323</pub-id></element-citation></ref><ref id="b0520"><label>104</label><element-citation publication-type="journal" id="h0520"><person-group person-group-type="author"><name><surname>Mauthe</surname><given-names>M.</given-names></name><name><surname>Orhon</surname><given-names>I.</given-names></name><name><surname>Rocchi</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Luhr</surname><given-names>M.</given-names></name><name><surname>Hijlkema</surname><given-names>K.-J.</given-names></name></person-group><article-title>Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion</article-title><source>Autophagy.</source><volume>14</volume><issue>8</issue><year>2018</year><fpage>1435</fpage><lpage>1455</lpage><pub-id pub-id-type="pmid">29940786</pub-id></element-citation></ref><ref id="b0525"><label>105</label><mixed-citation publication-type="other" id="h0525">ARENA CT. Coronavirus: Chloroquine yields positive data in Covid-19 trial 2020 FEBRUARY 18 [Available from: https://www.clinicaltrialsarena.com/news/coronavirus-covid-19-choroquine-data/.</mixed-citation></ref><ref id="b0530"><label>106</label><element-citation publication-type="journal" id="h0530"><person-group person-group-type="author"><name><surname>McChesney</surname><given-names>E.W.</given-names></name></person-group><article-title>Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate</article-title><source>The American journal of medicine.</source><volume>75</volume><issue>1</issue><year>1983</year><fpage>11</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">6408923</pub-id></element-citation></ref><ref id="b0535"><label>107</label><element-citation publication-type="book" id="h0535"><person-group person-group-type="author"><name><surname>Weniger</surname><given-names>H.</given-names></name><name><surname>Organization</surname><given-names>W.H.</given-names></name></person-group><chapter-title>Review of side effects and toxicity of chloroquine</chapter-title><year>1979</year><publisher-name>World health Organization</publisher-name><publisher-loc>Geneva</publisher-loc></element-citation></ref><ref id="b0540"><label>108</label><element-citation publication-type="journal" id="h0540"><person-group person-group-type="author"><name><surname>Laaksonen</surname><given-names>A.-L.</given-names></name><name><surname>Koskiahde</surname><given-names>V.</given-names></name><name><surname>Juva</surname><given-names>K.</given-names></name></person-group><article-title>Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus: a clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine</article-title><source>Scand. J. Rheumatol.</source><volume>3</volume><issue>2</issue><year>1974</year><fpage>103</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">4608161</pub-id></element-citation></ref><ref id="b0545"><label>109</label><element-citation publication-type="journal" id="h0545"><person-group person-group-type="author"><name><surname>Gautret</surname><given-names>P.</given-names></name><name><surname>Lagier</surname><given-names>J.-C.</given-names></name><name><surname>Parola</surname><given-names>P.</given-names></name><name><surname>Meddeb</surname><given-names>L.</given-names></name><name><surname>Mailhe</surname><given-names>M.</given-names></name><name><surname>Doudier</surname><given-names>B.</given-names></name></person-group><article-title>Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial</article-title><source>Int. J. Antimicrob. Agents</source><volume>105949</volume><year>2020</year></element-citation></ref><ref id="b0550"><label>110</label><element-citation publication-type="journal" id="h0550"><person-group person-group-type="author"><name><surname>Saghazadeh</surname><given-names>A.</given-names></name><name><surname>Rezaei</surname><given-names>N.</given-names></name></person-group><article-title>Immune-epidemiological parameters of the novel coronavirus &#x02013; a perspective</article-title><source>Expert Review of Clinical Immunology</source><year>2020</year></element-citation></ref><ref id="b0555"><label>111</label><element-citation publication-type="book" id="h0555"><person-group person-group-type="author"><name><surname>Channappanavar</surname><given-names>R.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name></person-group><chapter-title>editors. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Seminars in immunopathology</chapter-title><year>2017</year><publisher-name>Springer</publisher-name></element-citation></ref><ref id="b0560"><label>112</label><element-citation publication-type="journal" id="h0560"><person-group person-group-type="author"><name><surname>Cameron</surname><given-names>M.J.</given-names></name><name><surname>Bermejo-Martin</surname><given-names>J.F.</given-names></name><name><surname>Danesh</surname><given-names>A.</given-names></name><name><surname>Muller</surname><given-names>M.P.</given-names></name><name><surname>Kelvin</surname><given-names>D.J.</given-names></name></person-group><article-title>Human immunopathogenesis of severe acute respiratory syndrome (SARS)</article-title><source>Virus Res.</source><volume>133</volume><issue>1</issue><year>2008</year><fpage>13</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">17374415</pub-id></element-citation></ref><ref id="b0565"><label>113</label><element-citation publication-type="journal" id="h0565"><person-group person-group-type="author"><name><surname>Min</surname><given-names>C.-K.</given-names></name><name><surname>Cheon</surname><given-names>S.</given-names></name><name><surname>Ha</surname><given-names>N.-Y.</given-names></name><name><surname>Sohn</surname><given-names>K.M.</given-names></name><name><surname>Kim</surname><given-names>Y.</given-names></name><name><surname>Aigerim</surname><given-names>A.</given-names></name></person-group><article-title>Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity</article-title><source>Sci. Rep.</source><volume>6</volume><issue>1</issue><year>2016</year><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">28442746</pub-id></element-citation></ref><ref id="b0570"><label>114</label><mixed-citation publication-type="other" id="h0570">He J, Tao H, Yan Y, Huang S-Y, Xiao Y. Molecular mechanism of evolution and human infection with the novel coronavirus (2019-nCoV). bioRxiv. 2020.</mixed-citation></ref><ref id="b0575"><label>115</label><element-citation publication-type="journal" id="h0575"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Ma</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name></person-group><article-title>The potential role of IL-6 in monitoring coronavirus disease</article-title><source>Available at SSRN</source><volume>3548761</volume><year>2019</year><fpage>2020</fpage></element-citation></ref><ref id="b0580"><label>116</label><element-citation publication-type="journal" id="h0580"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Fu</surname><given-names>B.</given-names></name><name><surname>Zheng</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Zhao</surname><given-names>C.</given-names></name><name><surname>Qi</surname><given-names>Y.</given-names></name></person-group><article-title>Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+ CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus</article-title><source>BioRxiv.</source><year>2020</year></element-citation></ref><ref id="b0585"><label>117</label><element-citation publication-type="journal" id="h0585"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Shi</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name></person-group><article-title>Pathological findings of COVID-19 associated with acute respiratory distress syndrome</article-title><source>The Lancet respiratory medicine.</source><volume>8</volume><issue>4</issue><year>2020</year><fpage>420</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">32085846</pub-id></element-citation></ref><ref id="b0590"><label>118</label><mixed-citation publication-type="other" id="h0590">Liu Y, Sun W, Li J, Chen L, Wang Y, Zhang L, et al. Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019. MedRxiv. 2020.</mixed-citation></ref><ref id="b0595"><label>119</label><element-citation publication-type="journal" id="h0595"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>D.M.</given-names></name><name><surname>Teachey</surname><given-names>D.T.</given-names></name><name><surname>Grupp</surname><given-names>S.A.</given-names></name></person-group><article-title>Toxicity management for patients receiving novel T-cell engaging therapies</article-title><source>Curr. Opin. Pediatr.</source><volume>26</volume><issue>1</issue><year>2014</year><fpage>43</fpage><pub-id pub-id-type="pmid">24362408</pub-id></element-citation></ref><ref id="b0600"><label>120</label><element-citation publication-type="journal" id="h0600"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Geng</surname><given-names>M.</given-names></name><name><surname>Peng</surname><given-names>Y.</given-names></name><name><surname>Meng</surname><given-names>L.</given-names></name><name><surname>Lu</surname><given-names>S.</given-names></name></person-group><article-title>Molecular immune pathogenesis and diagnosis of COVID-19</article-title><source>J. Pharm. Anal.</source><year>2020</year></element-citation></ref><ref id="b0605"><label>121</label><element-citation publication-type="journal" id="h0605"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>T.J.</given-names></name><name><surname>Brand</surname><given-names>O.J.</given-names></name><name><surname>Morgan</surname><given-names>D.J.</given-names></name><name><surname>Salek-Ardakani</surname><given-names>S.</given-names></name><name><surname>Jagger</surname><given-names>C.</given-names></name><name><surname>Fujimori</surname><given-names>T.</given-names></name></person-group><article-title>Defective lung function following influenza virus is due to prolonged, reversible hyaluronan synthesis</article-title><source>Matrix Biol.</source><volume>80</volume><year>2019</year><fpage>14</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">29933044</pub-id></element-citation></ref><ref id="b0610"><label>122</label><element-citation publication-type="journal" id="h0610"><person-group person-group-type="author"><name><surname>Collum</surname><given-names>S.D.</given-names></name><name><surname>Chen</surname><given-names>N.Y.</given-names></name><name><surname>Hernandez</surname><given-names>A.M.</given-names></name><name><surname>Hanmandlu</surname><given-names>A.</given-names></name><name><surname>Sweeney</surname><given-names>H.</given-names></name><name><surname>Mertens</surname><given-names>T.C.</given-names></name></person-group><article-title>Inhibition of hyaluronan synthesis attenuates pulmonary hypertension associated with lung fibrosis</article-title><source>Br. J. Pharmacol.</source><volume>174</volume><issue>19</issue><year>2017</year><fpage>3284</fpage><lpage>3301</lpage><pub-id pub-id-type="pmid">28688167</pub-id></element-citation></ref><ref id="b0615"><label>123</label><element-citation publication-type="journal" id="h0615"><person-group person-group-type="author"><name><surname>Maschalidi</surname><given-names>S.</given-names></name><name><surname>Sepulveda</surname><given-names>F.E.</given-names></name><name><surname>Garrigue</surname><given-names>A.</given-names></name><name><surname>Fischer</surname><given-names>A.</given-names></name><name><surname>de Saint</surname><given-names>Basile G.</given-names></name></person-group><article-title>Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice</article-title><source>Blood, The Journal of the American Society of Hematology.</source><volume>128</volume><issue>1</issue><year>2016</year><fpage>60</fpage><lpage>71</lpage></element-citation></ref><ref id="b0620"><label>124</label><element-citation publication-type="journal" id="h0620"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>M.B.</given-names></name><name><surname>Hildeman</surname><given-names>D.</given-names></name><name><surname>Kappler</surname><given-names>J.</given-names></name><name><surname>Marrack</surname><given-names>P.</given-names></name></person-group><article-title>An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder</article-title><source>Blood</source><volume>104</volume><issue>3</issue><year>2004</year><fpage>735</fpage><lpage>743</lpage><pub-id pub-id-type="pmid">15069016</pub-id></element-citation></ref><ref id="b0625"><label>125</label><element-citation publication-type="journal" id="h0625"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>J.D.</given-names></name><name><surname>Hildeman</surname><given-names>D.A.</given-names></name><name><surname>Johnson</surname><given-names>M.B.T.S.</given-names></name><name><surname>Terrell</surname><given-names>C.E.</given-names></name><name><surname>Millen</surname><given-names>S.H.</given-names></name></person-group><source>Etoposide Selectively Ablates Activated T.</source><year>2013</year></element-citation></ref><ref id="b0630"><label>126</label><element-citation publication-type="journal" id="h0630"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>W.M.</given-names></name><name><surname>Chevillotte</surname><given-names>M.D.</given-names></name><name><surname>Rice</surname><given-names>C.M.</given-names></name></person-group><article-title>Interferon-stimulated genes: a complex web of host defenses</article-title><source>Annu. Rev. Immunol.</source><volume>32</volume><year>2014</year><fpage>513</fpage><lpage>545</lpage><pub-id pub-id-type="pmid">24555472</pub-id></element-citation></ref><ref id="b0635"><label>127</label><element-citation publication-type="journal" id="h0635"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>R.B.</given-names></name><name><surname>Felton</surname><given-names>A.</given-names></name><name><surname>Kosak</surname><given-names>K.</given-names></name><name><surname>Kelsey</surname><given-names>D.K.</given-names></name><name><surname>Meschievitz</surname><given-names>C.K.</given-names></name></person-group><article-title>Prevention of experimental coronavirus colds with intranasal &#x003b1;-2b interferon</article-title><source>J. Infect. Dis.</source><volume>154</volume><issue>3</issue><year>1986</year><fpage>443</fpage><lpage>447</lpage><pub-id pub-id-type="pmid">3016111</pub-id></element-citation></ref><ref id="b0640"><label>128</label><mixed-citation publication-type="other" id="h0640">Mosaddeghi P, Negahdaripour M, Dehghani Z, Farahmandnejad M, Moghadami M, Nezafat N, et al. Therapeutic approaches for COVID-19 based on the dynamics of interferon-mediated immune responses. 2020.</mixed-citation></ref><ref id="b0645"><label>129</label><element-citation publication-type="journal" id="h0645"><person-group person-group-type="author"><name><surname>Golchin</surname><given-names>A.</given-names></name><name><surname>Farahany</surname><given-names>T.Z.</given-names></name><name><surname>Khojasteh</surname><given-names>A.</given-names></name><name><surname>Soleimanifar</surname><given-names>F.</given-names></name><name><surname>Ardeshirylajimi</surname><given-names>A.</given-names></name></person-group><article-title>The clinical trials of mesenchymal stem cell therapy in skin diseases: an update and concise review</article-title><source>Curr. Stem Cell Res. Ther.</source><volume>14</volume><issue>1</issue><year>2019</year><fpage>22</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">30210006</pub-id></element-citation></ref><ref id="b0650"><label>130</label><element-citation publication-type="journal" id="h0650"><person-group person-group-type="author"><name><surname>Uccelli</surname><given-names>A.</given-names></name><name><surname>de Rosbo</surname><given-names>N.K.</given-names></name></person-group><article-title>The immunomodulatory function of mesenchymal stem cells: mode of action and pathways</article-title><source>Ann. N. Y. Acad. Sci.</source><volume>1351</volume><issue>1</issue><year>2015</year><fpage>114</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">26152292</pub-id></element-citation></ref><ref id="b0655"><label>131</label><element-citation publication-type="journal" id="h0655"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells</article-title><source>ChinaXiv</source><year>2020</year></element-citation></ref><ref id="b0660"><label>132</label><element-citation publication-type="journal" id="h0660"><person-group person-group-type="author"><name><surname>Leng</surname><given-names>Z.</given-names></name><name><surname>Zhu</surname><given-names>R.</given-names></name><name><surname>Hou</surname><given-names>W.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Han</surname><given-names>Q.</given-names></name></person-group><article-title>Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia</article-title><source>Aging and disease.</source><volume>11</volume><issue>2</issue><year>2020</year><fpage>216</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">32257537</pub-id></element-citation></ref><ref id="b0665"><label>133</label><element-citation publication-type="journal" id="h0665"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Cao</surname><given-names>W.</given-names></name><name><surname>Shi</surname><given-names>Y.</given-names></name></person-group><article-title>Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications</article-title><source>Nat. Immunol.</source><volume>15</volume><issue>11</issue><year>2014</year><fpage>1009</fpage><pub-id pub-id-type="pmid">25329189</pub-id></element-citation></ref><ref id="b0670"><label>134</label><element-citation publication-type="journal" id="h0670"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Cao</surname><given-names>K.</given-names></name><name><surname>Liu</surname><given-names>K.</given-names></name><name><surname>Xue</surname><given-names>Y.</given-names></name><name><surname>Roberts</surname><given-names>A.I.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Kynurenic acid, an IDO metabolite, controls TSG-6-mediated immunosuppression of human mesenchymal stem cells</article-title><source>Cell Death Differ.</source><volume>25</volume><issue>7</issue><year>2018</year><fpage>1209</fpage><lpage>1223</lpage><pub-id pub-id-type="pmid">29238069</pub-id></element-citation></ref><ref id="b0675"><label>135</label><mixed-citation publication-type="other" id="h0675">Van Erp EA, Luytjes W, Ferwerda G, Van Kasteren PB. Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease. Frontiers in immunology. 2019;10.</mixed-citation></ref><ref id="b0680"><label>136</label><mixed-citation publication-type="other" id="h0680">Gunn BM, Yu W-H, Karim MM, Brannan JM, Herbert AS, Wec AZ, et al. A role for Fc function in therapeutic monoclonal antibody-mediated protection against Ebola virus. Cell host &#x00026; microbe. 2018;24(2):221-33. e5.</mixed-citation></ref><ref id="b0685"><label>137</label><element-citation publication-type="journal" id="h0685"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>K.-M.</given-names></name><name><surname>Chiueh</surname><given-names>T.-S.</given-names></name><name><surname>Siu</surname><given-names>L.</given-names></name><name><surname>Lin</surname><given-names>J.-C.</given-names></name><name><surname>Chan</surname><given-names>P.K.</given-names></name><name><surname>Peng</surname><given-names>M.-Y.</given-names></name></person-group><article-title>Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital</article-title><source>J. Antimicrob. Chemother.</source><volume>56</volume><issue>5</issue><year>2005</year><fpage>919</fpage><lpage>922</lpage><pub-id pub-id-type="pmid">16183666</pub-id></element-citation></ref><ref id="b0690"><label>138</label><element-citation publication-type="journal" id="h0690"><person-group person-group-type="author"><name><surname>Mair-Jenkins</surname><given-names>J.</given-names></name><name><surname>Saavedra-Campos</surname><given-names>M.</given-names></name><name><surname>Baillie</surname><given-names>J.K.</given-names></name><name><surname>Cleary</surname><given-names>P.</given-names></name><name><surname>Khaw</surname><given-names>F.-M.</given-names></name><name><surname>Lim</surname><given-names>W.S.</given-names></name></person-group><article-title>The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis</article-title><source>J. Infect. Dis.</source><volume>211</volume><issue>1</issue><year>2015</year><fpage>80</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">25030060</pub-id></element-citation></ref><ref id="b0695"><label>139</label><element-citation publication-type="journal" id="h0695"><person-group person-group-type="author"><name><surname>Shanmugaraj</surname><given-names>B.</given-names></name><name><surname>Siriwattananon</surname><given-names>K.</given-names></name><name><surname>Wangkanont</surname><given-names>K.</given-names></name></person-group><article-title>Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)</article-title><source>Asian Pac. J. Allergy Immunol.</source><year>2020</year></element-citation></ref><ref id="b0700"><label>140</label><mixed-citation publication-type="other" id="h0700">Cheng Y, Wong R, Soo Y, Wong W, Lee C, Ng M, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. European Journal of Clinical Microbiology and Infectious Diseases. 2005;24(1):44-6.</mixed-citation></ref><ref id="b0705"><label>141</label><mixed-citation publication-type="other" id="h0705">Law PK. Emergent Serum Therapy and Antibody Medicine to Counteract Sudden Attacks of COVID-19 and Other Pathogenic Epidemics. Scientific Research Publishing; 2020.</mixed-citation></ref><ref id="b0710"><label>142</label><element-citation publication-type="journal" id="h0710"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>F.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name></person-group><article-title>Treatment of 5 critically ill patients with COVID-19 with convalescent plasma</article-title><source>JAMA</source><year>2020</year></element-citation></ref><ref id="b0715"><label>143</label><mixed-citation publication-type="other" id="h0715">Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study. medRxiv. 2020.</mixed-citation></ref><ref id="b0720"><label>144</label><element-citation publication-type="journal" id="h0720"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Xiong</surname><given-names>J.</given-names></name><name><surname>Bao</surname><given-names>L.</given-names></name><name><surname>Shi</surname><given-names>Y.</given-names></name></person-group><article-title>Convalescent plasma as a potential therapy for COVID-19</article-title><source>Lancet. Infect. Dis</source><volume>20</volume><issue>4</issue><year>2020</year><fpage>398</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">32113510</pub-id></element-citation></ref><ref id="b0725"><label>145</label><mixed-citation publication-type="other" id="h0725">(FDA) FaDA. Recommendations for Investigational COVID-19 Convalescent Plasma 2020 April 13 [Available from: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma.</mixed-citation></ref><ref id="b0730"><label>146</label><mixed-citation publication-type="other" id="h0730">(FDA) FaDA. Coronavirus (COVID-19) Update: FDA Encourages Recovered Patients to Donate Plasma for Development of Blood-Related Therapies 2020 April 16 [Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-encourages-recovered-patients-donate-plasma-development-blood.</mixed-citation></ref><ref id="b0735"><label>147</label><element-citation publication-type="journal" id="h0735"><person-group person-group-type="author"><name><surname>Busch</surname><given-names>M.P.</given-names></name><name><surname>Bloch</surname><given-names>E.M.</given-names></name><name><surname>Kleinman</surname><given-names>S.</given-names></name></person-group><article-title>Prevention of transfusion-transmitted infections</article-title><source>Blood</source><volume>133</volume><issue>17</issue><year>2019</year><fpage>1854</fpage><lpage>1864</lpage><pub-id pub-id-type="pmid">30808637</pub-id></element-citation></ref><ref id="b0740"><label>148</label><element-citation publication-type="journal" id="h0740"><person-group person-group-type="author"><name><surname>Hendrickson</surname><given-names>J.E.</given-names></name><name><surname>Hillyer</surname><given-names>C.D.</given-names></name></person-group><article-title>Noninfectious serious hazards of transfusion</article-title><source>Anesth. Analg.</source><volume>108</volume><issue>3</issue><year>2009</year><fpage>759</fpage><lpage>769</lpage><pub-id pub-id-type="pmid">19224780</pub-id></element-citation></ref><ref id="b0745"><label>149</label><mixed-citation publication-type="other" id="h0745">Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. 2020.</mixed-citation></ref><ref id="b0750"><label>150</label><element-citation publication-type="journal" id="h0750"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>F.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name></person-group><article-title>Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma</article-title><source>JAMA</source><year>2020</year></element-citation></ref><ref id="b0755"><label>151</label><element-citation publication-type="journal" id="h0755"><person-group person-group-type="author"><name><surname>Raj</surname><given-names>V.S.</given-names></name><name><surname>Mou</surname><given-names>H.</given-names></name><name><surname>Smits</surname><given-names>S.L.</given-names></name><name><surname>Dekkers</surname><given-names>D.H.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M.A.</given-names></name><name><surname>Dijkman</surname><given-names>R.</given-names></name></person-group><article-title>Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC</article-title><source>Nature</source><volume>495</volume><issue>7440</issue><year>2013</year><fpage>251</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">23486063</pub-id></element-citation></ref><ref id="b0760"><label>152</label><mixed-citation publication-type="other" id="h0760">360dx. Coronavirus Test Tracker: Commercially Available COVID-19 Diagnostic Tests 2020 April 15 [Available from: https://www.360dx.com/coronavirus-test-tracker-launched-covid-19-tests.</mixed-citation></ref><ref id="b0765"><label>153</label><element-citation publication-type="journal" id="h0765"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>A.</given-names></name><name><surname>Xia</surname><given-names>S.</given-names></name><name><surname>Lu</surname><given-names>S.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name></person-group><article-title>Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody</article-title><source>Emerging Microbes Infect.</source><volume>9</volume><issue>1</issue><year>2020</year><fpage>382</fpage><lpage>385</lpage></element-citation></ref><ref id="b0770"><label>154</label><element-citation publication-type="journal" id="h0770"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Pan</surname><given-names>Z.</given-names></name><name><surname>Qian</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>You</surname><given-names>R.</given-names></name></person-group><article-title>Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor</article-title><source>Cell. Mol. Immunol.</source><volume>1&#x02013;3</volume><year>2020</year></element-citation></ref><ref id="b0775"><label>155</label><element-citation publication-type="journal" id="h0775"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Drabek</surname><given-names>D.</given-names></name><name><surname>Okba</surname><given-names>N.M.</given-names></name><name><surname>van Haperen</surname><given-names>R.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name></person-group><article-title>A human monoclonal 1 antibody blocking SARS-CoV-2 infection</article-title><source>Biorxiv.</source><year>2020</year></element-citation></ref><ref id="b0780"><label>156</label><element-citation publication-type="journal" id="h0780"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Potential interventions for novel coronavirus in China: A systematic review</article-title><source>J. Med. Virol.</source><year>2020</year></element-citation></ref><ref id="b0785"><label>157</label><mixed-citation publication-type="other" id="h0785">Bian H, Zheng Z-H, Wei D, Zhang Z, Kang W-Z, Hao C-Q, et al. Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. medRxiv. 2020.</mixed-citation></ref><ref id="b0790"><label>158</label><element-citation publication-type="journal" id="h0790"><person-group person-group-type="author"><name><surname>Momattin</surname><given-names>H.</given-names></name><name><surname>Al-Ali</surname><given-names>A.Y.</given-names></name><name><surname>Al-Tawfiq</surname><given-names>J.A.</given-names></name></person-group><article-title>A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV)</article-title><source>Travel Med. Infect. Dis.</source><volume>30</volume><year>2019</year><fpage>9</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">31252170</pub-id></element-citation></ref><ref id="b0795"><label>159</label><element-citation publication-type="journal" id="h0795"><person-group person-group-type="author"><name><surname>Jawhara</surname><given-names>S.</given-names></name></person-group><article-title>Could intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID-19 and strengthen the immune system of new patients?</article-title><source>Int. J. Mol. Sci.</source><volume>21</volume><issue>7</issue><year>2020</year><fpage>2272</fpage></element-citation></ref><ref id="b0800"><label>160</label><element-citation publication-type="journal" id="h0800"><person-group person-group-type="author"><name><surname>De Ranieri</surname><given-names>D.</given-names></name><name><surname>Fenny</surname><given-names>N.S.</given-names></name></person-group><article-title>Intravenous immunoglobulin in the treatment of primary immunodeficiency diseases</article-title><source>Pediatr. Ann.</source><volume>46</volume><issue>1</issue><year>2017</year><fpage>e8</fpage><lpage>e12</lpage><pub-id pub-id-type="pmid">28079912</pub-id></element-citation></ref><ref id="b0805"><label>161</label><element-citation publication-type="journal" id="h0805"><person-group person-group-type="author"><name><surname>Galeotti</surname><given-names>C.</given-names></name><name><surname>Kaveri</surname><given-names>S.V.</given-names></name><name><surname>Bayry</surname><given-names>J.</given-names></name></person-group><article-title>IVIG-mediated effector functions in autoimmune and inflammatory diseases</article-title><source>Int. Immunol.</source><volume>29</volume><issue>11</issue><year>2017</year><fpage>491</fpage><lpage>498</lpage><pub-id pub-id-type="pmid">28666326</pub-id></element-citation></ref><ref id="b0810"><label>162</label><element-citation publication-type="journal" id="h0810"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.-T.</given-names></name><name><surname>Sheng</surname><given-names>W.-H.</given-names></name><name><surname>Fang</surname><given-names>C.-T.</given-names></name><name><surname>Chen</surname><given-names>Y.-C.</given-names></name><name><surname>Wang</surname><given-names>J.-L.</given-names></name><name><surname>Yu</surname><given-names>C.-J.</given-names></name></person-group><article-title>Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients</article-title><source>Emerg. Infect. Dis.</source><volume>10</volume><issue>5</issue><year>2004</year><fpage>818</fpage><pub-id pub-id-type="pmid">15200814</pub-id></element-citation></ref><ref id="b0815"><label>163</label><element-citation publication-type="journal" id="h0815"><person-group person-group-type="author"><name><surname>Arabi</surname><given-names>Y.M.</given-names></name><name><surname>Arifi</surname><given-names>A.A.</given-names></name><name><surname>Balkhy</surname><given-names>H.H.</given-names></name><name><surname>Najm</surname><given-names>H.</given-names></name><name><surname>Aldawood</surname><given-names>A.S.</given-names></name><name><surname>Ghabashi</surname><given-names>A.</given-names></name></person-group><article-title>Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection</article-title><source>Ann. Intern. Med.</source><volume>160</volume><issue>6</issue><year>2014</year><fpage>389</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">24474051</pub-id></element-citation></ref><ref id="b0820"><label>164</label><element-citation publication-type="book" id="h0820"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Bai</surname><given-names>T.</given-names></name><name><surname>Fan</surname><given-names>H.</given-names></name><name><surname>Hong</surname><given-names>K.</given-names></name><name><surname>Song</surname><given-names>H.</given-names></name></person-group><chapter-title>editors. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open forum infectious diseases</chapter-title><year>2020</year><publisher-name>Oxford University Press US</publisher-name></element-citation></ref><ref id="b0825"><label>165</label><element-citation publication-type="journal" id="h0825"><person-group person-group-type="author"><name><surname>Cavalli</surname><given-names>G.</given-names></name><name><surname>De Luca</surname><given-names>G.</given-names></name><name><surname>Campochiaro</surname><given-names>C.</given-names></name><name><surname>Della-Torre</surname><given-names>E.</given-names></name><name><surname>Ripa</surname><given-names>M.</given-names></name><name><surname>Canetti</surname><given-names>D.</given-names></name></person-group><article-title>Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. The Lancet</article-title><source>Rheumatology</source><year>2020</year></element-citation></ref><ref id="b0830"><label>166</label><mixed-citation publication-type="other" id="h0830">Hub AE. Coronavirus (COVID-19) Update: Early Safety Signals Around Ibuprofen and Renin-Angiotensin Inhibitors 2020 March 23 [Available from: https://edhub.ama-assn.org/jn-learning/audio-player/18329925.</mixed-citation></ref><ref id="b0835"><label>167</label><mixed-citation publication-type="other" id="h0835">Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. British Medical Journal Publishing Group; 2020.</mixed-citation></ref><ref id="b0840"><label>168</label><element-citation publication-type="journal" id="h0840"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>L.</given-names></name><name><surname>Karakiulakis</surname><given-names>G.</given-names></name><name><surname>Roth</surname><given-names>M.</given-names></name></person-group><article-title>Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet</article-title><source>Respir. Med.</source><year>2020</year></element-citation></ref><ref id="b0845"><label>169</label><element-citation publication-type="journal" id="h0845"><person-group person-group-type="author"><name><surname>Monteil</surname><given-names>V.</given-names></name><name><surname>Kwon</surname><given-names>H.</given-names></name><name><surname>Prado</surname><given-names>P.</given-names></name><name><surname>Hagelkr&#x000fc;ys</surname><given-names>A.</given-names></name><name><surname>Wimmer</surname><given-names>R.A.</given-names></name><name><surname>Stahl</surname><given-names>M.</given-names></name></person-group><article-title>Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2</article-title><source>Cell</source><year>2020</year></element-citation></ref><ref id="b0850"><label>170</label><element-citation publication-type="journal" id="h0850"><person-group person-group-type="author"><name><surname>Shmakov</surname><given-names>S.</given-names></name><name><surname>Smargon</surname><given-names>A.</given-names></name><name><surname>Scott</surname><given-names>D.</given-names></name><name><surname>Cox</surname><given-names>D.</given-names></name><name><surname>Pyzocha</surname><given-names>N.</given-names></name><name><surname>Yan</surname><given-names>W.</given-names></name></person-group><article-title>Diversity and evolution of class 2 CRISPR&#x02013;Cas systems</article-title><source>Nat. Rev. Microbiol.</source><volume>15</volume><issue>3</issue><year>2017</year><fpage>169</fpage><pub-id pub-id-type="pmid">28111461</pub-id></element-citation></ref><ref id="b0855"><label>171</label><mixed-citation publication-type="other" id="h0855">Smargon AA, Cox DB, Pyzocha NK, Zheng K, Slaymaker IM, Gootenberg JS, et al. Cas13b is a type VI-B CRISPR-associated RNA-guided RNase differentially regulated by accessory proteins Csx27 and Csx28. Molecular cell. 2017;65(4):618-30. e7.</mixed-citation></ref><ref id="b0860"><label>172</label><element-citation publication-type="journal" id="h0860"><person-group person-group-type="author"><name><surname>Gootenberg</surname><given-names>J.S.</given-names></name><name><surname>Abudayyeh</surname><given-names>O.O.</given-names></name><name><surname>Lee</surname><given-names>J.W.</given-names></name><name><surname>Essletzbichler</surname><given-names>P.</given-names></name><name><surname>Dy</surname><given-names>A.J.</given-names></name><name><surname>Joung</surname><given-names>J.</given-names></name></person-group><article-title>Nucleic acid detection with CRISPR-Cas13a/C2c2</article-title><source>Science</source><volume>356</volume><issue>6336</issue><year>2017</year><fpage>438</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">28408723</pub-id></element-citation></ref><ref id="b0865"><label>173</label><element-citation publication-type="journal" id="h0865"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Q.</given-names></name><name><surname>Shi</surname><given-names>Y.</given-names></name></person-group><article-title>Coronavirus disease (COVID-19) and neonate: What neonatologist need to know</article-title><source>J. Med. Virol.</source><year>2020</year></element-citation></ref><ref id="b0870"><label>174</label><mixed-citation publication-type="other" id="h0870">Berra L, Lei C, Su B, Dong H, Fakhr BS, Grassi LG, et al. Protocol for a randomized controlled trial testing inhaled nitric oxide therapy in spontaneously breathing patients with COVID-19. medRxiv. 2020.</mixed-citation></ref><ref id="b0875"><label>175</label><element-citation publication-type="book" id="h0875"><person-group person-group-type="author"><name><surname>Organization</surname><given-names>W.H.</given-names></name></person-group><chapter-title>Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020</chapter-title><year>2020</year><publisher-name>World Health Organization</publisher-name></element-citation></ref><ref id="b0880"><label>176</label><mixed-citation publication-type="other" id="h0880">Nowak JK, Walkowiak J. Is lithium a potential treatment for the novel Wuhan (2019-nCoV) coronavirus? A scoping review. F1000Research. 2020;9(93):93.</mixed-citation></ref><ref id="b0885"><label>177</label><mixed-citation publication-type="other" id="h0885">Zhang J, Ma X, Yu F, Liu J, Zou F, Pan T, et al. Teicoplanin potently blocks the cell entry of 2019-nCoV. bioRxiv. 2020.</mixed-citation></ref><ref id="b0890"><label>178</label><element-citation publication-type="journal" id="h0890"><person-group person-group-type="author"><name><surname>Caly</surname><given-names>L.</given-names></name><name><surname>Druce</surname><given-names>J.D.</given-names></name><name><surname>Catton</surname><given-names>M.G.</given-names></name><name><surname>Jans</surname><given-names>D.A.</given-names></name><name><surname>Wagstaff</surname><given-names>K.M.</given-names></name></person-group><article-title>The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro</article-title><source>Antiviral Res.</source><volume>104787</volume><year>2020</year></element-citation></ref><ref id="b0895"><label>179</label><element-citation publication-type="journal" id="h0895"><person-group person-group-type="author"><name><surname>Kelleni</surname><given-names>M.</given-names></name></person-group><article-title>Nitazoxanide/Azithromycin Combination for COVID- 19: A Suggested New Protocol for COVID-19 Early</article-title><source>Management.</source><year>2020</year></element-citation></ref><ref id="b0900"><label>180</label><mixed-citation publication-type="other" id="h0900">Kaplan MM, editor The use of methotrexate, colchicine, and other immunomodulatory drugs in the treatment of primary biliary cirrhosis. Seminars in liver disease; 1997: &#x000a9; 1997 by Thieme Medical Publishers, Inc.</mixed-citation></ref><ref id="b0905"><label>181</label><mixed-citation publication-type="other" id="h0905">(WHO) WHO. &#x0201c;Solidarity&#x0201d; clinical trial for COVID-19 treatments 2020 April 21 [Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments.</mixed-citation></ref><ref id="b0910"><label>182</label><element-citation publication-type="journal" id="h0910"><person-group person-group-type="author"><name><surname>Nagai</surname><given-names>A.</given-names></name><name><surname>Matsumiya</surname><given-names>H.</given-names></name><name><surname>Hayashi</surname><given-names>M.</given-names></name><name><surname>Yasui</surname><given-names>S.</given-names></name><name><surname>Okamoto</surname><given-names>H.</given-names></name><name><surname>Konno</surname><given-names>K.</given-names></name></person-group><article-title>Effects of nicotinamide and niacin on bleomycin-induced acute injury and subsequent fibrosis in hamster lungs</article-title><source>Exp. Lung Res.</source><volume>20</volume><issue>4</issue><year>1994</year><fpage>263</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">7527336</pub-id></element-citation></ref><ref id="b0915"><label>183</label><element-citation publication-type="journal" id="h0915"><person-group person-group-type="author"><name><surname>Hemil&#x000e4;</surname><given-names>H.</given-names></name></person-group><article-title>Vitamin C intake and susceptibility to the common cold</article-title><source>Br. J. Nutr.</source><volume>77</volume><issue>1</issue><year>1997</year><fpage>59</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">9059230</pub-id></element-citation></ref><ref id="b0920"><label>184</label><mixed-citation publication-type="other" id="h0920">Wang L-s, Wang Y-r, Ye D-w, Liu Q-q. A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence. International Journal of Antimicrobial Agents. 2020:105948.</mixed-citation></ref><ref id="b0925"><label>185</label><mixed-citation publication-type="other" id="h0925">London IC. Report 13: Estimating the number of infections and the impact of non-pharmaceutical interventions on COVID-19 in 11 European countries 2020 March 30 [Available from: https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/.</mixed-citation></ref><ref id="b0930"><label>186</label><element-citation publication-type="journal" id="h0930"><person-group person-group-type="author"><name><surname>Kissler</surname><given-names>S.M.</given-names></name><name><surname>Tedijanto</surname><given-names>C.</given-names></name><name><surname>Goldstein</surname><given-names>E.</given-names></name><name><surname>Grad</surname><given-names>Y.H.</given-names></name><name><surname>Lipsitch</surname><given-names>M.</given-names></name></person-group><article-title>Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period</article-title><source>Science</source><year>2020:</year><fpage>eabb5793</fpage></element-citation></ref></ref-list></back></article>